Medtronic (MDT)

Company ID: 40 | CIK: 0001613103
10-Q view:
No 10-K data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data

Business Unit / Product Segments

Major Customers (% of Revenue)

No major-customer concentration data found.

Operational KPIs

Deferred revenue (backlog)

No 10-K data

Sales and administrative offices (branches)

No 10-Q data

Pelvic mesh claims (claims_count)

No 10-K data

Shareholders of record (customers)

Countries served (customers_served)

No 10-K data

Employee Engagement Survey Participation (engagement)

No 10-Q data

Employees (headcount)

780G launch countries (other)

No 10-K data

Accrued litigation (other)

No 10-K data

Airway & Ventilator sales mix (other)

No 10-Q data

Average repurchase price (other)

No 10-K data

CLMS agreements (other)

Cash and cash equivalents (other)

No 10-K data

Cash and current investments (other)

No 10-K data

Cash and investments (other)

No 10-K data

Cath lab agreements (other)

No 10-K data

Cath lab managed services agreements (other)

No 10-Q data

China revenue share (other)

Commercial paper outstanding (other)

No 10-K data

Cost synergies achieved (other)

Cost synergies target (other)

No 10-K data

Countries of operation (other)

No 10-K data

Countries served (other)

Countries with sales offices (other)

No 10-Q data

Credit facility available (other)

No 10-K data

Currency derivative notional (other)

No 10-K data

Currency impact on net sales (other)

No 10-K data

Current ratio (other)

No 10-K data

Deferred Revenue (other)

No 10-K data

Deferred revenue (other)

No 10-K data

Diabetes pump plaintiffs (other)

No 10-K data

Diabetes pump retainer ring lawsuits (other)

No 10-K data

Dividends declared per share (other)

No 10-K data

Dividends per share (other)

No 10-K data

Effective tax rate (other)

No 10-K data

Emerging market sales growth (other)

No 10-K data

Emerging markets net sales growth (other)

No 10-K data

Emerging markets sales growth (other)

No 10-K data

Employee Resource Group Members (other)

No 10-Q data

Employee resource group members (other)

No 10-Q data

Employee survey response rate (other)

No 10-Q data

Ethnically diverse U.S. managers share (other)

No 10-Q data

Ethnically diverse U.S. workforce share (other)

No 10-Q data

Ethnically diverse workforce (other)

No 10-Q data

Expected annual gross savings (other)

No 10-K data

Facilities owned share (other)

No 10-Q data

Free cash flow (other)

No 10-K data

Global Gender Pay Equity (other)

No 10-Q data

Global Workforce Gender Diversity (other)

No 10-Q data

Global gender pay equity (other)

No 10-Q data

Gross margin (other)

No 10-K data

Hernia mesh plaintiffs (other)

No 10-K data

INFUSE claimants (other)

No 10-K data

INFUSE claims (other)

No 10-K data

INFUSE claims settled (other)

No 10-K data

Internal Fill Rate (other)

No 10-Q data

Internal hire rate (other)

No 10-Q data

Investments (other)

No 10-K data

Manufacturing facilities (other)

No 10-Q data

Net sales growth (other)

No 10-K data

Non-GAAP nominal tax rate (other)

No 10-K data

Number of Reportable Segments (other)

Ordinary Shares outstanding (other)

No 10-Q data

Ordinary shares outstanding (other)

Organizational Health Survey response rate (other)

No 10-Q data

Pay equity (other)

No 10-Q data

Pay equity — U.S. (other)

No 10-Q data

Pay equity — global gender (other)

No 10-Q data

Pelvic mesh claimants (other)

No 10-K data

Pelvic mesh claims (other)

No 10-K data

Pelvic mesh claims asserted (other)

No 10-K data

Pelvic mesh claims settled (other)

No 10-K data

People Leaders Gender Diversity (other)

No 10-Q data

Price adjustment rebates (other)

No 10-K data

Pro forma net sales (other)

No 10-K data

R&D expense (other)

No 10-Q data

R&D expense percent of sales (other)

No 10-K data

Remaining buyback authorization (other)

No 10-K data

Remaining share repurchase authorization (other)

No 10-K data

Restructuring accrual balance (other)

No 10-K data

Restructuring reserve (other)

No 10-K data

Return of free cash flow (other)

No 10-K data

Return of operating cash flow (other)

No 10-K data

Return to shareholders (other)

No 10-K data

Revenue from deferred revenue (other)

No 10-K data

Revenue recognized from deferred revenue (other)

No 10-K data

SG&A expense percent of sales (other)

No 10-K data

Sales and administrative office locations (other)

No 10-Q data

Sales and administrative offices (other)

No 10-Q data

Sales office locations (other)

No 10-Q data

Settled pelvic mesh claims (other)

No 10-K data

Share repurchase authorization remaining (other)

No 10-K data

Shareholders of record (other)

No 10-Q data

Shares outstanding (other)

No 10-K data

Shares repurchased (other)

No 10-K data

Total debt (other)

No 10-K data

Total external debt (other)

No 10-K data

U.S. Ethnic Pay Equity (other)

No 10-Q data

U.S. Gender Pay Equity (other)

No 10-Q data

U.S. Workforce Ethnic Diversity (other)

No 10-Q data

U.S. ethnic pay equity (other)

No 10-Q data

U.S. gender pay equity (other)

No 10-Q data

U.S.-based employee share (other)

No 10-Q data

Ventilator product line revenue (other)

No 10-K data

Women in management (other)

No 10-Q data

Women in workforce (other)

No 10-Q data

Women people leaders (other)

No 10-Q data

Women share of global workforce (other)

No 10-Q data

Women share of managers (other)

No 10-Q data

Workforce diversity (other)

No 10-Q data

Working capital (other)

No 10-K data

HVAD patients implanted (patients)

Facilities (properties)

Revenue, Remaining Performance Obligation, Amount (rpo)

Ordinary Shares outstanding (shares)

No 10-Q data

Ordinary Shares outstanding (shares_outstanding)

No 10-Q data

Manufacturing and research space (square_footage)

No 10-Q data

MiniMed 670G active users (users)

Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

Demographics

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data

HCM Metrics — Point-in-Time

No 10-Q data
No 10-Q data

HCM Metrics — Flow (Annual / YTD)

No flow HCM metrics found.

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-07-31restructuringin_progress2025-12-012029-04-30MiniMed separation-related; costs not recorded in a specific reportable segmentUSD 300 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board-approved actions to support the MiniMed separation; expected pre-tax charges of approximately $300-$500 million between Q3 FY2026 and finalization of the Transition Services Agreement (no later than 24 months after the March 9, 2026 IPO). Materially all charges relate to employee termination benefits, with potential contract termination costs and asset write-offs. $201 million incurred since inception; Q1 FY2027 charges of $67 million ($58 million in restructuring charges, net; $8 million in SG&A). Restructuring liability of $93 million at July 31, 2026.
2026-07-31restructuringin_progressUSD 23 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Individually immaterial restructuring activities during the quarter; costs primarily employee termination benefits, facility and contract termination costs, and asset write-offs. Restructuring liability of $42 million at July 31, 2026.
2026-07-31restructuringin_progress2025-122029Company-wide (Medtronic and MiniMed separation-related organizations)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved December 2025; expected pre-tax charges of $300M-$500M total (charge value left null because only a range is disclosed). $67M recognized in Q1 FY2027 (SG&A $8M, restructuring line $58M); $201M incurred since inception. Severance liability $93M at 2026-07-31. Actions include organizational realignments, workforce actions, and separation of duplicated shared services; completion tied to Transition Services Agreement, no later than 24 months after the 2026-03-09 MiniMed IPO. No employee counts disclosed.
2026-07-31restructuringin_progressVarious (individually immaterial activities)USD 23 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 FY2027 total restructuring, associated and other costs of $23M (COGS $8M, SG&A $2M, restructuring line $13M); includes employee termination benefits, facility/contract termination, asset write-offs. No employee counts or announcement dates disclosed.
2026-07-31acquisition_additioncompleted2026-06-122026-06-12Neuroscience Portfolio — Specialty Therapies divisionbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closed 2026-06-12; total purchase price $681M (incl. $123M contingent consideration). Headcount added not disclosed.
2026-07-31acquisition_additioncompleted2026-07-162026-07-16Neuroscience Portfolio — Neuromodulation divisionbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closed 2026-07-16; total purchase price $654M cash. Headcount added not disclosed.
2026-07-31divestiture_reductionin_progress2025-052027-04-30Diabetes Business (MiniMed Group, Inc.)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Intent to separate announced May 2025; MiniMed IPO completed 2026-03-09 (Medtronic retains ~90.03% ownership, still consolidated). Company plans to complete separation within fiscal year 2027 (expected completion date is end of FY2027 per filing). Headcount removed not disclosed; MiniMed remains consolidated so no workforce reduction recognized to date.
2026-07-31restructuringin_progress2025-12-012029-04-30GlobalMiniMed Separation / Shared ServicesUSD 67 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Board approved actions in Dec 2025 to support MiniMed separation. Total expected pre-tax charges $300M-$500M. Q1 FY27 incurred $67M ($58M restructuring, $9M SG&A). Since inception, $201M incurred. Materially all charges relate to employee termination benefits.
2026-07-31restructuringin_progressGlobalOther Immaterial ActivitiesUSD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Individually immaterial restructuring activities. Q1 FY27 incurred $23M ($13M restructuring, $8M COGS, $2M SG&A). Primarily employee termination benefits, facility/contract termination costs, and asset write-offs.
2026-07-31acquisition_additioncompletedGlobalNeuroscience Portfoliobusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Scientia Vascular (June 12, 2026) and SPR Therapeutics (July 16, 2026). Headcount not disclosed.
2026-07-31restructuringin_progressEmployee Severance [Member] / MiniMed Restructuring Actions [Member]USD 62,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-07-31restructuringin_progressAssociated And Other Costs [Member] / MiniMed Restructuring Actions [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-07-31restructuringin_progressMiniMed Restructuring Actions [Member]USD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-07-31restructuringin_progressEmployee Severance [Member] / Other Restructuring Activities [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-07-31restructuringin_progressAssociated And Other Costs [Member] / Other Restructuring Activities [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-07-31restructuringin_progressOther Restructuring Activities [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-07-31restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 89,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-04-24restructuringin_progress2025-122029MiniMed separation support (not recorded in a specific reportable segment)USD 136 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Board-approved December 2025 program supporting the Medtronic/MiniMed separation via organizational realignments, workforce-related actions, and separation of duplicated shared services. Expected pre-tax charges of approximately $300-$500 million, materially all employee termination benefits; $136 million recognized in FY2026 with a $119 million severance accrual remaining at year-end. Completion expected in fiscal 2029, tied to the Transition Services Agreement concluding no later than 24 months after the March 9, 2026 MiniMed IPO. Headcount affected not disclosed.
2026-04-24restructuringin_progress2025-12Diabetes BusinessUSD 118 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan approved December 2025 to terminate a third-party manufacturing agreement within the Diabetes Business; $118 million pre-tax charges comprise $84 million of asset write-offs in cost of products sold and $34 million of contract termination costs in other operating expense. No workforce impact quantified.
2026-04-24restructuringin_progress2025-12-012029-04-30GlobalCorporate / shared services (Medtronic and MiniMed)USD 400 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board approved December 2025; program expected to result in pre-tax charges of approximately $300M to $500M (midpoint shown as 400). $136M recognized in restructuring charges, net during FY2026. Charges incurred between Q3 FY2026 and finalization of the Transition Services Agreement (no later than 24 months after the March 9, 2026 IPO). No employee count disclosed.
2026-04-24plant_closurecompleted2025-12-01GlobalDiabetes BusinessUSD 118 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		December 2025 plan to terminate a third-party manufacturing agreement within the Diabetes Business; $84M asset write-offs in cost of products sold and $34M contract termination costs in other operating expense. No employee count disclosed.
2026-04-24acquisition_additioncompleted2026-04-202026-04-20IsraelCardiovascular — Coronary & Peripheral Vascularbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired remaining 85% of CathWorks for $525M consideration ($718M total purchase price). No headcount added disclosed.
2026-04-24acquisition_additionannounced2026-05-202026-10-31United StatesNeuroscience — Neuromodulationsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Intent to acquire SPR Therapeutics announced May 20, 2026; ~$650M expected consideration; expected to close in first half of FY2027. No headcount disclosed.
2026-04-24acquisition_additioncompleted2026-06-122026-06-12United StatesNeurosciencebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closed June 12, 2026 (subsequent to fiscal year-end); ~$550M upfront plus up to $375M contingent consideration. Purchase price allocation incomplete; no headcount disclosed.
2026-04-24divestiture_reductionin_progress2025-05-012027-04-30GlobalDiabetes Business (MiniMed Group, Inc.)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Separation of Diabetes Business via IPO completed March 9, 2026 (10% sold; Medtronic retains ~90.03%). Company plans to complete full separation within the next fiscal year. No headcount removed disclosed.
2026-04-24restructuringin_progress2025-12-012029-04-25GlobalDiabetes Business / MiniMedUSD 300 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Board approved actions in Dec 2025 to support separation of Diabetes Business. Expected pre-tax charges $300M-$500M. Materially all charges relate to employee termination benefits. Completion expected by FY2029.
2026-04-24restructuringcompleted2025-12-012026-04-24GlobalDiabetes BusinessUSD 118 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Termination of third-party manufacturing agreement within Diabetes Business. $84M asset write-offs in COGS, $34M contract termination in other operating expense.
2026-04-24restructuringin_progress2025-12-012029-04-25GlobalDiabetes Business / MiniMedUSD 300 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		MiniMed Restructuring Actions approved Dec 2025. Expected pre-tax charges $300M-$500M. FY2026 charges recorded: $136M. Completion expected FY2029. Employee count not disclosed.
2026-04-24restructuringcompleted2025-12-012026-04-24GlobalDiabetes BusinessUSD 118 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Termination of third-party manufacturing agreement within Diabetes Business. Pre-tax charges $118M ($84M asset write-offs, $34M contract termination). Employee count not disclosed.
2026-04-24restructuringin_progressEmployee Severance [Member] / MiniMed Restructuring Activities [Member]USD 136,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2026-04-24restructuringin_progressEmployee Severance [Member] / Other Restructuring Activities [Member]USD 88,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2026-04-24restructuringin_progressAssociated and Other Costs [Member] / Other Restructuring Activities [Member]USD 66,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2026-04-24restructuringin_progressOther Restructuring Activities [Member]USD 154,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2026-04-24restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 370,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2026-01-23restructuringin_progress2025-122029MiniMed separation support; costs not recorded in a specific reportable segmentUSD 16 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Board approved restructuring actions in December 2025 to support the Diabetes business separation into MiniMed Group, Inc. Expected pre-tax charges of approximately $300 million to $500 million incurred at varying intervals between Q3 FY2026 and finalization of the Transition Services Agreement (concluding no later than 24 months after MiniMed IPO completion). Materially all charges expected to relate to employee termination benefits. $16 million recognized in Q3 FY2026, all employee termination benefits, recorded in restructuring charges, net and within other accrued expenses.
2026-01-23othercompleted2025-12Diabetes Operating UnitUSD 118 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Management approved and committed to a plan to terminate a third-party manufacturing agreement within the Diabetes Operating Unit. Pre-tax charges of $118 million, including $84 million of asset write-offs in cost of products sold and $34 million of contract termination costs in other operating expense (income), net.
2026-01-23restructuringin_progress2025-12-012029-04-30GlobalMedtronic and MiniMed (corporate, shared services, and operating functions)USD 400 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved Dec 2025; expected pre-tax charges of $300M–$500M (midpoint shown). $16M recognized in Q3 FY2026. Charges incurred between Q3 FY2026 and finalization of Transition Services Agreement; completion expected FY2029. Employee headcount impact not disclosed.
2026-01-23restructuringin_progress2025-12-01GlobalDiabetes Operating UnitUSD 118 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Management approved plan to terminate a third-party manufacturing agreement; $84M asset write-offs in cost of products sold and $34M contract termination costs in other operating expense. Employee headcount impact not disclosed.
2026-01-23restructuringin_progress2025-12-012029-04-25GlobalMiniMed / Diabetes Operating UnitUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Board approved actions in Dec 2025 to support MiniMed separation. Total expected pre-tax charges $300M-$500M. Q3 recognized $16M for employee termination benefits. Completion expected by FY2029.
2026-01-23restructuringin_progress2025-12-01GlobalDiabetes Operating UnitUSD 118 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan to terminate third-party manufacturing agreement. Recorded $118M pre-tax charges: $84M asset write-offs (Cost of products sold) and $34M contract termination costs (Other operating expense).
2026-01-23restructuringin_progressUSD 172,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-23restructuringin_progressEmployee Severance [Member] / MiniMed Restructuring Actions [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-23restructuringin_progressCost of Sales [Member] / Other Restructuring Acitivities [Member]USD 89,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-23restructuringin_progressSelling, General and Administrative Expenses [Member] / Other Restructuring Acitivities [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-23restructuringin_progressRestructuring Charges [Member] / Other Restructuring Acitivities [Member]USD 60,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-23restructuringin_progressOther Restructuring Acitivities [Member]USD 156,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-01-23restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 172,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-10-24restructuringin_progressUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Three months ended October 24, 2025 restructuring, associated, and other costs of $13 million (vs. $46 million prior-year quarter), primarily employee termination benefits and facility/contract termination costs. No employee counts disclosed. Total restructuring charges, net line item was $10 million for the quarter.
2025-10-24restructuringin_progressUSD 79 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six months ended October 24, 2025 restructuring, associated, and other costs of $79 million (vs. $108 million prior-year period), primarily employee termination benefits and facility/contract termination costs. Restructuring liability roll-forward shows $92 million of charges and $175 million of cash payments during the period, ending balance $52 million. No employee counts disclosed.
2025-10-24divestiture_reductionannounced2025-05-01Diabetes Operating UnitMD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Company announced intent in May 2025 to separate the Diabetes business into a new independent, publicly traded company, expected to be completed within 18 months of announcement. Headcount impact not quantified. SG&A increase in the period partly attributed to expenses supporting the impending separation.
2025-10-24restructuringin_progressGlobalCompany-wideUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring, associated, and other costs were $13M for the quarter and $79M YTD, primarily employee termination benefits plus facility and contract termination costs; no employee counts or completion dates disclosed. Restructuring accrual balance was $52M at quarter-end, down from $150M at fiscal year-end.
2025-10-24restructuringin_progressUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily relate to employee termination benefits and facility/contract termination costs for the three months ended Oct 24, 2025. Employee count not disclosed.
2025-10-24restructuringin_progressUSD 79 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily relate to employee termination benefits and facility/contract termination costs for the six months ended Oct 24, 2025. Employee count not disclosed.
2025-10-24restructuringin_progressUSD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-10-24restructuringin_progressCost of Sales [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-10-24restructuringin_progressSelling, General and Administrative Expenses [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-10-24restructuringin_progressRestructuring Charges [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-10-24restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-25restructuringin_progressUSD 67 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Total restructuring, associated, and other costs of $67 million for the three months ended July 25, 2025, primarily employee termination benefits and facility/contract termination costs. No employee counts disclosed. Charges of $73 million were recorded in the quarter against the accrual.
2025-07-25divestiture_reductionannounced2025-05-012026-11-01Diabetes Operating Unitother
f5-10q / GLM-5.3-flash-fp4-HTML		Company announced intent in May 2025 to separate the Diabetes business into a new independent publicly traded company, expected to be completed within 18 months of the announcement. No headcount figures disclosed.
2025-07-25restructuringin_progressUSD 73 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 FY2026 accrual roll-forward shows $73M of charges ($52M employee termination benefits for involuntary terminations, $21M associated and other costs); income statement restructuring charges, net was $45M and total restructuring, associated and other costs were $67M. Number of employees affected, announcement date, geography, and completion timing are not disclosed.
2025-07-25divestiture_reductionannounced2025-052026-11Diabetes Operating UnitMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		In May 2025 the company announced intent to separate the Diabetes business into a new independent, publicly traded company, expected to complete within 18 months of announcement. No headcount associated with the separation is disclosed.
2025-07-25restructuringin_progressUSD 67 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily relate to employee termination benefits for involuntarily terminated employees and facility/contract termination costs. Employee count not disclosed.
2025-07-25restructuringin_progressUSD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-25restructuringin_progressCost of Sales [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-25restructuringin_progressSelling, General and Administrative Expenses [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-25restructuringin_progressRestructuring Charges [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-07-25restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-04-25divestiture_reductionannounced2025-052026-11Diabetes Operating Unitsubsequent_events
f5-10k / GLM-5.3-flash-HTML		Announced intent to separate the Diabetes business into a new independent, publicly traded company; segment headcount not disclosed. Completion expected within 18 months of the May 2025 announcement (estimated November 2026).
2025-04-25restructuringin_progressUSD 303 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2025 cost reduction initiatives including employee termination benefits, facility consolidations, asset write-downs, and contract terminations. Roll-forward shows $240M of employee termination benefit charges in FY2025; $150M accrual remained at April 25, 2025. No employee count disclosed.
2025-04-25restructuringin_progressGlobalMultipleUSD 303 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2025 restructuring and associated costs; includes employee termination benefits, facility consolidations, asset write-downs, and contract terminations. Employee headcount affected not disclosed.
2025-04-25divestiture_reductionannounced2025-05-012026-11-01GlobalDiabetes Operating Unitsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		May 2025 announcement of intent to separate Diabetes business into independent public company; expected completion within 18 months of announcement. Headcount impact not disclosed.
2025-04-25restructuringin_progressGlobalVariousUSD 303 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Fiscal year 2025 restructuring costs of $303 million primarily related to cost reduction initiatives including employee termination benefits, facility consolidations, asset write-downs, and contract terminations. Specific headcount not disclosed.
2025-04-25restructuringin_progress2024-04-28GlobalVariousUSD 303 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cost reduction initiatives including employee termination benefits, facility consolidations, asset write-downs, and contract terminations. Employee count not explicitly disclosed in footnote.
2025-04-25restructuringin_progressCost of Sales [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-04-25restructuringin_progressSelling, General and Administrative Expenses [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-04-25restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 303,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-01-24restructuringin_progressUSD 46 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Ongoing cost-reduction restructuring program; three-month charge of $46 million (total restructuring and associated costs), primarily employee termination benefits and facility consolidations. No employee counts disclosed.
2025-01-24restructuringin_progressUSD 154 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month (year-to-date) restructuring and associated costs of $154 million, primarily employee termination benefits and facility consolidations to support cost reduction initiatives. No employee counts disclosed.
2025-01-24restructuringin_progressUSD 46 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 FY2025 restructuring and associated costs of $46M ($154M YTD), primarily employee termination benefits and facility consolidations; no employee count disclosed. Accrual for employee termination benefits fell from $136M to $61M during the nine months.
2025-01-24acquisition_additioncompletedMedical Surgicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 FY2025 acquisitions with $128M fair value of net assets acquired (including $108M goodwill, $50M IPR&D); results of acquired businesses not significant individually or in aggregate; no headcount added disclosed.
2025-01-24restructuringin_progressUSD 43 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to employee termination benefits and facility consolidations. Employee count not disclosed.
2025-01-24restructuringin_progressUSD 120 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Nine months ended Jan 24, 2025. Charges primarily related to employee termination benefits and facility consolidations. Employee count not disclosed.
2025-01-24restructuringin_progressUSD 46,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-24restructuringin_progressCost of Sales [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-24restructuringin_progressSelling, General and Administrative Expenses [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-24restructuringin_progressRestructuring Charges [Member]USD 43,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-01-24restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 46,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-10-25restructuringin_progressUSD 46 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Total restructuring and associated costs for the three months ended October 25, 2024; primarily employee termination benefits and facility consolidations for cost reduction initiatives. No employee counts disclosed.
2024-10-25restructuringin_progressUSD 108 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Total restructuring and associated costs for the six months ended October 25, 2024; primarily employee termination benefits and facility consolidations for cost reduction initiatives. No employee counts disclosed.
2024-10-25restructuringin_progressUSD 46 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 FY2025 restructuring and associated costs of $46M ($108M YTD), primarily employee termination benefits and facility consolidations for cost reduction. Filer does not disclose number of employees affected or completion timing. Severance accrual roll-forward: $147M at 2024-04-26 to $70M at 2024-10-25, with $87M of employee termination benefit charges and $156M cash payments YTD.
2024-10-25restructuringin_progressUSD 46 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges for three months ended Oct 25, 2024 primarily related to employee termination benefits and facility consolidations. Employee count not disclosed.
2024-10-25restructuringin_progressUSD 108 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges for six months ended Oct 25, 2024 primarily related to employee termination benefits and facility consolidations. Employee count not disclosed.
2024-10-25restructuringin_progressUSD 46,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-10-25restructuringin_progressCost of Sales [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-10-25restructuringin_progressSelling, General and Administrative Expenses [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-10-25restructuringin_progressRestructuring Charges [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-10-25restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 46,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-26restructuringin_progressUSD 62 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Quarterly restructuring and associated costs of $62 million (vs. $91 million prior year), primarily employee termination benefits and facility consolidations for cost reduction initiatives; no employee counts disclosed. Total charges of $71 million recorded, of which $47 million in restructuring charges, net, $9 million in cost of products sold, and $5 million in SG&A. Restructuring liability balance of $119 million at July 26, 2024.
2024-07-26restructuringin_progressUSD 62 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Costs for the quarter comprise employee termination benefits and facility consolidations supporting cost reduction initiatives; no employee counts, announcement dates, or completion timelines are disclosed. Severance accrual roll-forward: $147M at 2024-04-26, charges $71M, cash payments $87M, non-cash settlements $3M, accrual adjustments $(9)M, $119M at 2024-07-26.
2024-07-26restructuringin_progressUSD 62 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Incurred $62 million in restructuring and associated costs primarily related to employee termination benefits and facility consolidations. Specific headcount affected not disclosed.
2024-07-26restructuringin_progressUSD 62,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-26restructuringin_progressCost of Sales [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-26restructuringin_progressSelling, General and Administrative Expenses [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-26restructuringin_progressRestructuring Charges [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-07-26restructuringin_progressSegment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]USD 62,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-04-26restructuringannounced2024-02-20Medical Surgical — ventilator product line (remaining PMRI businesses combined into Acute Care & Monitoring)USD 439 (millions)other
f5-10k / GLM-5.3-flash-HTML		Decision to exit ventilator product line. FY2024 pre-tax charges include $295M intangible impairments, $70M inventory write-downs, plus contract cancellation costs and severance; no headcount figure disclosed. Company will honor existing contracts during wind-down.
2024-04-26restructuringin_progressUSD 389 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal 2024 cost-reduction actions primarily for employee termination benefits and facility consolidations; year-end severance liability of $147M remained ($136M termination benefits). No affected-headcount target disclosed; distinct from ventilator exit charges.
2024-04-26restructuringin_progressGlobalEnterprise-wideUSD 389 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fiscal year 2024 restructuring and associated costs for employee termination benefits and facility consolidations supporting cost reduction; employee counts and completion dates not disclosed. Ending accrual was $147 million at fiscal year-end.
2024-04-26restructuringin_progress2024-02-20GlobalMedical Surgical — ventilator product line (moved to Other operating segment)USD 439 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pre-tax exit charges recorded in fiscal year 2024, including $371 million of non-cash impairments and write-downs ($295 million intangibles, $70 million inventory) plus contract cancellation and severance; $369 million in other operating expense and $70 million in cost of products sold. Company continues to honor existing ventilator contracts. Headcount affected not disclosed.
2024-04-26acquisition_additioncompletedNot disclosedPrimarily Cardiovascular (goodwill and IPR&D recorded)USD 335 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Value is the acquisition-date fair value of net assets acquired during fiscal year 2024 (including $131 million goodwill and $150 million IPR&D), not a charge. Individual acquisitions not named and headcount added not disclosed; results of acquired businesses described as not significant individually or in aggregate.
2024-04-26restructuringcompleted2023-04-292024-04-26GlobalVariousUSD 389 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		FY2024 restructuring costs primarily related to employee termination benefits and facility consolidations to support cost reduction initiatives. No specific employee count disclosed for FY2024 actions.
2024-04-26restructuringcompleted2022-04-302023-04-28GlobalVariousUSD 647 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		FY2023 restructuring charges primarily related to Enterprise Excellence and Simplification programs, plus incremental employee termination benefits. No specific employee count disclosed.
2024-04-26restructuringcompleted2024-04-262024-04-26GlobalVariousUSD 389 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		FY2024 restructuring costs primarily related to employee termination benefits and facility consolidations. Specific headcount not disclosed.
2024-04-26restructuringcompleted2023-04-282023-04-28GlobalVariousUSD 647 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		FY2023 restructuring costs primarily related to Enterprise Excellence and Simplification programs, including voluntary early retirement packages. Specific headcount not disclosed.
2024-04-26restructuringin_progressUSD 389,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-04-26restructuringin_progressCost of Sales [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-04-26restructuringin_progressSelling, General and Administrative Expenses [Member]USD 108,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-04-26restructuringin_progressRestructuring Charges [Member]USD 226,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-04-26restructuringin_progressSegment Reconciling Items [Member]USD 389,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-01-26restructuringin_progressUSD 237 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month restructuring and associated costs of $237 million (three months: $55 million) primarily for employee termination benefits and facility consolidations supporting cost reduction initiatives; no employee counts disclosed. Restructuring liability at January 26, 2024 was $63 million.
2024-01-26otherannounced2024-02-20Medical Surgical — Patient Monitoring & Respiratory Interventions (ventilator product line)USD 388 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Company announced exit of ventilator product line and combination of remaining PMRI businesses into Acute Care and Monitoring unit. Estimated pre-tax charge of $350-$425 million (midpoint shown), mostly non-cash impairment of long-lived intangible assets, majority expected in quarter ending April 26, 2024. Workforce impact not quantified; existing ventilator contracts will be honored.
2024-01-26restructuringin_progressGlobalEnterprise-wideUSD 237 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month restructuring and associated costs for employee termination benefits and facility consolidations supporting cost reduction; no employee count disclosed. Q3 portion was $55 million.
2024-01-26restructuringannounced2024-02-20GlobalMedical Surgical — Patient Monitoring & Respiratory Interventions (ventilator product line)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to exit ventilator product line and combine remaining PMRI businesses into Acute Care and Monitoring unit. Estimated pre-tax charge of $350M to $425M, majority expected in quarter ending 2024-04-26, primarily non-cash intangible impairment. Ventilator revenue was $111M for nine months ended 2024-01-26. No employee count disclosed.
2024-01-26restructuringin_progressUSD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Incurred $55 million in restructuring and associated costs primarily related to employee termination benefits and facility consolidations for the three months ended Jan 26, 2024.
2024-01-26restructuringin_progressUSD 237 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Incurred $237 million in restructuring and associated costs primarily related to employee termination benefits and facility consolidations for the nine months ended Jan 26, 2024.
2024-01-26plant_closureannounced2024-02-20Medical SurgicalUSD 388 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced decision to exit ventilator product line. Expects pre-tax charge of $350M-$425M, majority in Q4 FY2024, primarily for non-cash impairment of long-lived intangible assets.
2024-01-26restructuringin_progressUSD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-01-26restructuringin_progressCost of Sales [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-01-26restructuringin_progressSelling, General and Administrative Expenses [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-01-26restructuringin_progressRestructuring Charges [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-01-26restructuringin_progressSegment Reconciling Items [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-27restructuringin_progressUSD 91 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cost reduction initiatives involving employee termination benefits and facility consolidations; three-month restructuring and associated costs of $91 million (six months: $182 million). No employee counts disclosed. Restructuring charges, net of $40 million for the quarter.
2023-10-27restructuringin_progressUSD 182 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended October 27, 2023 restructuring and associated costs ($91 million in the quarter), primarily employee termination benefits and facility consolidations for cost reduction; number of employees affected not disclosed. Employee termination benefit accrual fell from $204M to $72M over the six months.
2023-10-27restructuringin_progressUSD 91 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Incurred $91 million in restructuring and associated costs primarily related to employee termination benefits and facility consolidations for the three months ended Oct 27, 2023. Employee count affected not disclosed.
2023-10-27restructuringin_progressUSD 182 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Incurred $182 million in restructuring and associated costs primarily related to employee termination benefits and facility consolidations for the six months ended Oct 27, 2023. Employee count affected not disclosed.
2023-10-27restructuringin_progressUSD 91,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-27restructuringin_progressCost of Sales [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-27restructuringin_progressSelling, General and Administrative Expenses [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-27restructuringin_progressRestructuring Charges [Member]USD 40,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-27restructuringin_progressEmployee Severance [Member] / Enterprise Excellence and Simplification [Member]USD 94,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-27restructuringin_progressAssociated and Other Costs [Member] / Enterprise Excellence and Simplification [Member]USD 88,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-27restructuringin_progressEnterprise Excellence and Simplification [Member]USD 182,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-10-27restructuringin_progressSegment Reconciling Items [Member]USD 91,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-28restructuringin_progressUSD 91 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cost reduction initiatives involving employee termination benefits and facility consolidations; $91 million total restructuring and associated costs for the quarter, of which $54 million in restructuring charges, net. No employee counts disclosed.
2023-07-28restructuringin_progressGlobalEnterprise-wideUSD 91 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 FY2024 restructuring and associated costs for employee termination benefits and facility consolidations supporting cost reduction initiatives; no employee count disclosed.
2023-07-28acquisition_additionannounced2023-05-252023-12-31South KoreaDiabetesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreements to acquire EOFlow (EOPatch insulin delivery device); total consideration up to KRW 971 billion (~$760M); expected close in H2 CY2023; no headcount disclosed.
2023-07-28restructuringin_progressUSD 91 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Incurred $91 million of restructuring and associated costs related to employee termination benefits and facility consolidations to support cost reduction initiatives. Employee count not disclosed.
2023-07-28restructuringin_progressEmployee Severance [Member]USD 91,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-28restructuringin_progressCost of Sales [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-28restructuringin_progressSelling, General and Administrative Expenses [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-28restructuringin_progressRestructuring Charges [Member]USD 54,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-28restructuringin_progressUSD 91,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-28restructuringin_progressEmployee Severance [Member] / Enterprise Excellence and Simplification [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-28restructuringin_progressAssociated Costs [Member] / Enterprise Excellence and Simplification [Member]USD 37,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-28restructuringin_progressOther Restructuring [Member] / Enterprise Excellence and Simplification [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-28restructuringin_progressEnterprise Excellence and Simplification [Member]USD 92,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-28restructuringin_progressSegment Reconciling Items [Member]USD 91,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-04-28restructuringcompletedGlobalEnterprise-wide (global operations, functional and commercial optimization)USD 1,800 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year Enterprise Excellence program; the $1.8 billion is the cumulative total pre-tax program charge, not the fiscal 2023 amount. Program substantially completed as of fiscal 2023 year-end. Employee counts not disclosed.
2023-04-28restructuringcompletedGlobalEnterprise-wide (innovation, customer experience, revenue growth)USD 500 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year Simplification program; the $0.5 billion is the cumulative total pre-tax program charge, not the fiscal 2023 amount. Substantially completed as of fiscal 2023 year-end. Employee counts not disclosed.
2023-04-28restructuringin_progressGlobalEnterprise-wide cost reduction initiativesUSD 300 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Charges incurred in the fourth quarter of fiscal 2023, primarily employee termination benefits; incremental to the Enterprise Excellence and Simplification programs. Fiscal 2023 total restructuring and associated costs were $647 million. Employee counts not disclosed.
2023-04-28voluntary_separationcompletedUnited StatesEligible U.S. employees (primarily U.S. pension plan participants)USD 94 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Voluntary early retirement packages offered during fiscal 2023; charge comprises incremental defined benefit, defined contribution, and post-retirement expenses recognized in restructuring charges, net (accounted for under pension rules, excluded from the restructuring roll-forward table). Employee counts not disclosed.
2023-04-28acquisition_additioncompleted2022-05-132022-05-13Neurosciencebusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired all outstanding shares at $28.25 per share on May 13, 2022; total consideration net of cash acquired was $1.2 billion. Headcount added not disclosed.
2023-04-28acquisition_additioncompleted2022-08-302022-08-30Cardiovascularbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Privately-held cardiac mapping/navigation and ablation company acquired August 30, 2022 for $904 million net of cash acquired. Headcount added not disclosed.
2023-04-28divestiture_reductioncompleted2022-05-252023-04-01Medical Surgical — Renal Care Solutions (RCS)USD 136 (millions)other
f5-10k / GLM-5.3-flash-HTML		Definitive agreement with DaVita signed May 25, 2022; sale of half of the RCS business completed April 1, 2023 to form Mozarc Medical (50% equity interest retained). Fiscal 2023 charge of $136 million was non-cash, primarily goodwill impairment and disposal-group carrying value changes — not severance. Headcount transferred not disclosed.
2023-04-28divestiture_reductionannounced2022-102024-10Medical Surgical — Patient Monitoring and Respiratory InterventionsMD&A
f5-10k / GLM-5.3-flash-HTML		Intended separation of the combined Patient Monitoring and Respiratory Interventions businesses announced October 2022; completion expected 18 to 24 months from announcement (approximately April 2024 through October 2024). Separation-related charges recorded in Q4 fiscal 2023; headcount impact not disclosed.
2023-04-28acquisition_additionannounced2023-05-252023-12Diabetessubsequent_events
f5-10k / GLM-5.3-flash-HTML		Definitive agreements to acquire EOFlow, maker of the EOPatch tubeless disposable insulin delivery device; total consideration up to KRW 971 billion (approximately $738 million at May 25, 2023 rates). Expected to close in the second half of calendar 2023 subject to minimum tender condition and regulatory clearances. Headcount not disclosed.
2023-04-28restructuringcompleted2023-04-28GlobalEnterprise-wideUSD 647 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2023 total restructuring and associated costs across the Enterprise Excellence and Simplification programs, which were substantially complete at fiscal year-end; cumulative program pre-tax charges were $1.8B and $0.5B respectively. Employees affected not disclosed.
2023-04-28restructuringcompleted2023-04-28GlobalEnterprise-wideUSD 300 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Q4 FY2023 charges primarily for employee termination benefits supporting cost reduction initiatives; incremental to the Enterprise Excellence and Simplification programs and included within the $647M FY2023 total above (not additive).
2023-04-28voluntary_separationcompleted2023-04-28United StatesEnterprise-wideUSD 94 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Voluntary early retirement packages offered to eligible U.S. employees; charge is incremental defined benefit, defined contribution and post-retirement cost. Included within the $647M FY2023 restructuring total (not additive).
2023-04-28acquisition_additioncompleted2022-05-132022-05-13GlobalNeurosciencebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Intersect ENT completed May 13, 2022; total consideration $1.2B net of cash acquired. Headcount added not disclosed.
2023-04-28acquisition_additioncompleted2022-08-302022-08-30GlobalCardiovascularbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Affera completed August 30, 2022; total consideration $904M net of cash acquired. Headcount added not disclosed.
2023-04-28acquisition_additioncompleted2023-04-28GlobalMultiplebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Aggregate of other FY2023 business combinations; net assets acquired $123M. Headcount added not disclosed.
2023-04-28divestiture_reductioncompleted2022-05-252023-04-01GlobalMedical Surgical (Renal Care Solutions)USD 136 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of half of the Renal Care Solutions business to form Mozarc Medical, completed April 1, 2023; $136M non-cash pre-tax charges primarily for goodwill impairment and changes in carrying value of the disposal group. Headcount removed not disclosed.
2023-04-28otherannounced2022-10GlobalMedical Surgical (Patient Monitoring and Respiratory Interventions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Planned separation of the combined Patient Monitoring and Respiratory Interventions businesses announced October 2022, expected to complete 18 to 24 months after announcement. FY2023 divestiture and separation-related items of $235M include charges for this pending separation combined with Renal Care Solutions charges, so no separate charge is attributed here. Headcount impact not disclosed.
2023-04-28acquisition_additionannounced2023-05-25GlobalDiabetessubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: definitive agreements signed May 25, 2023 to acquire EOFlow; total consideration KRW 971 billion ($738M) if all public shares tender, expected to close in the second half of calendar 2023. Headcount added not disclosed.
2023-04-28restructuringcompletedGlobalEnterprise Excellence and Simplification programsUSD 647 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Total restructuring and associated costs for FY2023. Programs substantially completed by year-end. Includes $94M in incremental defined benefit/post-retirement expenses for voluntary early retirement packages.
2023-04-28voluntary_separationcompletedUnited StatesVariousUSD 94 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Incremental defined benefit, defined contribution, and post-retirement related expenses for employees accepting voluntary early retirement packages.
2023-04-28restructuringcompletedGlobalEnterprise Excellence and SimplificationUSD 647 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Includes Enterprise Excellence and Simplification programs substantially completed by year-end. Total pre-tax charges of $647 million for FY2023.
2023-04-28restructuringcompletedGlobalCost reduction initiativesUSD 300 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Incurred in Q4 FY2023, primarily related to employee termination benefits. Incremental to Enterprise Excellence and Simplification programs.
2023-04-28voluntary_separationcompletedUnited StatesRetirement BenefitsUSD 94 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Incremental defined benefit, defined contribution, and post-retirement related expenses for employees accepting voluntary early retirement packages.
2023-04-28restructuringin_progressIncremental Defined Benefit, Defined Contribution, And Post-Retirement Charges [Member]USD 94,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-04-28restructuringin_progressEmployee Severance [Member]USD 285,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-04-28restructuringin_progressAssociated Costs [Member]USD 271,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-04-28restructuringin_progressAsset Write-Downs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-04-28restructuringin_progressOther Restructuring [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-04-28restructuringin_progressUSD 564,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-01-27restructuringin_progress2023-04-28USD 104 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Enterprise Excellence and Simplification programs; three-month charges of $104M ($38M in restructuring charges, net; $26M in cost of products sold; $40M in SG&A). Company expects programs substantially completed by end of fiscal year 2023; expected completion date is fiscal year-end inferred from filing.
2023-01-27restructuringin_progress2023-04-28USD 275 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month total restructuring and associated costs for Enterprise Excellence and Simplification programs ($81M restructuring charges, net; $67M cost of products sold; $125M SG&A). Employee termination benefit charges of $85M and cash payments of $102M during the nine months; no employee counts disclosed.
2023-01-27divestiture_reductionannounced2022-05-25Medical Surgical — Renal Care SolutionsUSD 81 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Definitive agreement with DaVita to sell half of Renal Care Solutions business into a new kidney-care company; RCS classified as held for sale. Non-cash pre-tax charges of $81M in the nine months, primarily goodwill impairment; no headcount figures disclosed.
2023-01-27othercompleted2021-06-01Cardiovascular — Mechanical Circulatory Support (HVAD)USD 211 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		June 2021 decision to stop distribution and sale of HVAD System; charges included commitments and obligations for patient support, restructuring, and associated costs. Accruals of $84M in other accrued expenses and $104M in other liabilities at January 27, 2023; no employee counts disclosed.
2023-01-27restructuringin_progress2023-04-28GlobalEnterprise-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Enterprise Excellence program; no employee count disclosed. Lifetime program charges expected to total approximately $1.8 billion; nine-month charges across both programs (Enterprise Excellence and Simplification) were $275 million of total restructuring and associated costs, not split by program.
2023-01-27restructuringin_progress2023-04-28GlobalEnterprise-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Simplification program; no employee count disclosed. Lifetime program charges expected to total approximately $450 million; nine-month charges across both programs were $275 million of total restructuring and associated costs, not split by program. Both programs expected substantially complete by end of fiscal year 2023.
2023-01-27divestiture_reductionannounced2022-05-252023-04-28GlobalMedical Surgical — Renal Care SolutionsUSD 81 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell half of Renal Care Solutions business to DaVita; no headcount disclosed. Associated $81 million nine-month non-cash pre-tax charges relate primarily to goodwill impairment, not severance. Transaction expected to close in fiscal Q4 2023, subject to regulatory approvals.
2023-01-27restructuringin_progress2023-04-29GlobalEnterprise Excellence and SimplificationUSD 275 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to Enterprise Excellence and Simplification programs. Expected to be substantially completed by end of fiscal year. Employee termination benefits charges were $85 million for the nine months ended Jan 27, 2023.
2023-01-27acquisition_additioncompleted2022-05-13GlobalNeurosciencebusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Intersect ENT. Headcount not explicitly disclosed.
2023-01-27acquisition_additioncompleted2022-08-30GlobalCardiovascularbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Affera, Inc. Headcount not explicitly disclosed.
2023-01-27restructuringin_progressCost of Sales [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-27restructuringin_progressSelling, General and Administrative Expenses [Member]USD 40,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-27restructuringin_progressRestructuring Charges [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-27restructuringin_progressUSD 104,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-27restructuringin_progressEmployee Severance [Member] / Enterprise Excellence and Simplification [Member]USD 85,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-27restructuringin_progressAssociated Costs [Member] / Enterprise Excellence and Simplification [Member]USD 192,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-27restructuringin_progressOther Restructuring [Member] / Enterprise Excellence and Simplification [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-27restructuringin_progressEnterprise Excellence and Simplification [Member]USD 284,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-27restructuringin_progressSegment Reconciling Items [Member] / Restructurings Excluding RCS and MCS [Member]USD 104,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-27restructuringin_progressSegment Reconciling Items [Member] / Renal Care Business (RCS) [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-01-27restructuringin_progressSegment Reconciling Items [Member] / Mechanical Circulatory Support Operating Unit (MCS) [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-28restructuringin_progress2023-04-28All segmentsUSD 53 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Net charges of $53M in Q2 and $93M YTD; program inception-to-date costs $1.7B with ~$1.8B total expected by end of fiscal 2023. No employee counts disclosed.
2022-10-28restructuringin_progress2023-04-28All segmentsUSD 43 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Net charges of $43M in Q2 and $78M YTD; inception-to-date costs $427M with ~$450M total expected by end of fiscal 2023. No employee counts disclosed.
2022-10-28divestiture_reductionannounced2022-05-252023-12-31Medical Surgical — Renal Care SolutionsUSD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Agreement with DaVita to sell half of RCS business into a new kidney care company; expected to close in calendar 2023. Q2 charge $14M, YTD $81M, primarily goodwill impairment and disposal-group carrying amount changes. No headcount disclosed.
2022-10-28otherannounced2022-10-01Medical Surgical — Patient Monitoring and Respiratory InterventionsMD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Company announced intention to pursue a separation of the combined Patient Monitoring and Respiratory Interventions businesses, expected to complete 12 to 18 months from announcement. No headcount disclosed.
2022-10-28acquisition_additioncompleted2022-08-302022-08-30CardiovascularUSD 904 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Affera for $904M net of cash; adds cardiac mapping/navigation and ablation technologies. No headcount disclosed.
2022-10-28acquisition_additioncompleted2022-05-132022-05-13NeuroscienceUSD 1,200 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Intersect ENT for $1.2B total consideration net of cash acquired. No headcount disclosed.
2022-10-28restructuringin_progress20182023GlobalAll segmentsUSD 93 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in fiscal Q3 2018; charges of $53M in the quarter and $93M in the six months ended October 28, 2022, spread across restructuring charges, cost of products sold, and SG&A. Cumulative pre-tax costs of $1.7B since inception; approximately $1.8B total expected by end of fiscal 2023. No employee counts disclosed.
2022-10-28restructuringin_progress20202023GlobalAll segmentsUSD 78 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal Q1 2021; charges of $43M in the quarter and $78M in the six months ended October 28, 2022, including $31M in SG&A for the six-month period. Cumulative pre-tax costs of $427M since inception; approximately $450M total expected by end of fiscal 2023. No employee counts disclosed.
2022-10-28divestiture_reductionin_progress2022-05-252023GlobalMedical Surgical — Renal Care SolutionsUSD 81 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to sell half of the Renal Care Solutions business to DaVita Inc. to form an equally owned kidney-care company; business classified as held for sale. Non-cash pre-tax charges of $14M in the quarter and $81M in the six months, primarily goodwill impairment. Expected to close in calendar 2023, subject to approvals. No headcount impact disclosed.
2022-10-28otherin_progressUSD 37 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Exit of an unnamed business with charges of $37M in both the quarter and six months ended October 28, 2022, primarily inventory write-downs. Business, geography, timing, and headcount impact not disclosed.
2022-10-28divestiture_reductionannounced2022-10GlobalMedical Surgical — Patient Monitoring and Respiratory InterventionsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company announced its intention in October 2022 to pursue a separation of the combined Patient Monitoring and Respiratory Interventions businesses, expecting completion 12 to 18 months from announcement. No headcount impact or charges disclosed.
2022-10-28acquisition_additioncompleted2022-08-30Cardiovascularbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of privately held cardiac mapping and navigation developer; total consideration net of cash acquired of $904M, with $660M goodwill, $300M in-process R&D, and $201M contingent consideration. No headcount added disclosed.
2022-10-28acquisition_additioncompleted2022-05-13Neurosciencebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closed in the first quarter of fiscal 2023 (May 13, 2022) but disclosed in this filing; total consideration net of cash acquired of $1.2B. No headcount added disclosed.
2022-10-28acquisition_additioncompletedbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Aggregate of other acquisitions in the six months ended October 28, 2022 with net assets acquired of $123M ($66M goodwill, $57M technology intangibles) and $73M contingent consideration. Individual transactions and headcount not disclosed.
2022-10-28restructuringin_progress2018-07-012023-04-29GlobalAll segmentsUSD 53 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Enterprise Excellence program. Q2 2023 charges of $53M (3 months) / $93M (6 months). Total estimated costs ~$1.8B by end of FY2023. Employee count not disclosed.
2022-10-28restructuringin_progress2021-01-012023-04-29GlobalAll segmentsUSD 43 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Simplification program. Q2 2023 charges of $43M (3 months) / $78M (6 months). Total estimated costs ~$450M by end of FY2023. Employee count not disclosed.
2022-10-28restructuringcompleted2021-06-01GlobalCardiovascularUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Exit of HVAD System business. No new charges in Q2 2023. Prior charges included $515M impairments and $211M commitments. Accruals of $203M remain on balance sheet.
2022-10-28restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-28restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-28restructuringin_progressEmployee Severance [Member]USD 50,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-28restructuringin_progressAssociated Costs [Member]USD 126,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-28restructuringin_progressOther Restructuring [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-28restructuringin_progressUSD 180,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-28restructuringin_progressSegment Reconciling Items [Member] / Restructurings Excluding RCS and MCS [Member]USD 95,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-28restructuringin_progressSegment Reconciling Items [Member] / Renal Care Business (RCS) [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-10-28restructuringin_progressSegment Reconciling Items [Member] / Mechanical Circulatory Support Operating Unit (MCS) [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-29restructuringin_progress2017-10-012023-04-28GlobalAll segmentsUSD 40 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Multi-year program announced in Q3 FY2018; $1.6B incurred since inception, ~$1.8B total expected by end of FY2023. Q1 FY2023 charges of $40M include employee termination benefits, program salaries, and consulting costs. No employee count disclosed.
2022-07-29restructuringin_progress2020-05-012023-04-28GlobalAll segmentsUSD 36 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in Q1 FY2021; $385M incurred since inception, ~$450M total expected by end of FY2023. Q1 FY2023 charges of $36M include $21M employee termination benefits and $13M in SG&A. No employee count disclosed.
2022-07-29divestiture_reductionannounced2022-05-252023-12-31GlobalMedical Surgical — Renal Care SolutionsUSD 67 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell half of Renal Care Solutions business to DaVita to form a joint kidney care company; expected to close calendar 2023. $67M non-cash pre-tax impairment (primarily goodwill) recorded. Assets held for sale totaled $568M. No headcount disclosed.
2022-07-29acquisition_additioncompleted2022-05-132022-05-13GlobalNeuroscience — ENTbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Intersect ENT for $1.2B net of cash ($1.1B cash + $98M previously held investments) at $28.25/share. $615M goodwill, $683M intangibles acquired. No employee headcount disclosed.
2022-07-29acquisition_additionannounced2022-08-302022-08-30GlobalCardiovascular — Cardiac Ablationsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition of Affera for up to $1.0B including up to $250M contingent consideration. Preliminary purchase price allocation incomplete; no headcount disclosed.
2022-07-29restructuringin_progress2018-07-012023-04-29GlobalAll segmentsUSD 40 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Enterprise Excellence program. Q1 FY23 recognized net charges of $40 million ($19M in COGS, $28M in SG&A). Total estimated costs approx $1.8 billion by end of FY23. Employee count affected not disclosed for this period.
2022-07-29restructuringin_progress2021-01-012023-04-29GlobalAll segmentsUSD 36 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Simplification program. Q1 FY23 recognized net charges of $36 million ($13M in SG&A, $21M in restructuring charges net). Total estimated costs approx $450 million by end of FY23. Employee count affected not disclosed for this period.
2022-07-29acquisition_additioncompleted2022-05-132022-05-13GlobalNeurosciencebusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Intersect ENT for $1.2 billion. Expands Neuroscience portfolio. Headcount added not explicitly disclosed.
2022-07-29acquisition_additioncompleted2022-07-292022-07-29GlobalVariousbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other acquisitions with net assets of $123 million. Headcount added not explicitly disclosed.
2022-07-29acquisition_additionannounced2022-08-30GlobalCardiovascularUSD 1,000 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquired Affera, Inc. for up to $1.0 billion. Expands Cardiovascular portfolio. Headcount added not explicitly disclosed.
2022-07-29restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-29restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-29restructuringin_progressEmployee Severance [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-29restructuringin_progressAssociated Costs [Member]USD 61,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-29restructuringin_progressOther Restructuring [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-29restructuringin_progressUSD 85,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-29restructuringin_progressOther Operating Income (Expense) [Member] / Mechanical Circulatory Support [Member] / Cardiovascular [Member]USD 155,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-29restructuringin_progressSegment Reconciling Items [Member] / Restructurings Excluding RCS and MCS [Member]USD 76,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-29restructuringin_progressSegment Reconciling Items [Member] / Renal Care Business (RCS) [Member]USD 74,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-29restructuringin_progressMechanical Circulatory Support Operating Unit (MCS) [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-04-29restructuringin_progress20182023GlobalAll segments (global operations, functional optimization, commercial optimization)USD 259 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year Enterprise Excellence program announced in Q3 of fiscal year 2018. Fiscal 2022 net charges of $259 million ($31 million in restructuring charges, net; $116 million in cost of products sold; $112 million in SG&A). Cumulative charges since inception of $1.6 billion; estimated total approximately $1.8 billion by end of fiscal year 2023. Employee headcount impact not disclosed; announcement date precision limited to fiscal year/quarter.
2022-04-29restructuringin_progress20202023GlobalAll segmentsUSD 82 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Simplification program initiated in Q1 of fiscal year 2021 to make the company more nimble and competitive. Fiscal 2022 net charges of $82 million ($35 million in restructuring charges, net; $45 million in SG&A). Cumulative charges since inception of $349 million; estimated total approximately $450 million by end of fiscal year 2023. Employee headcount impact not disclosed.
2022-04-29restructuringcompleted2021-06-03GlobalCardiovascular — Mechanical Circulatory Support (MCS) Operating UnitUSD 881 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Decision to stop distribution and sale of the Medtronic HVAD System. Fiscal 2022 charges of $726 million in Q1 ($58 million in cost of products sold; $668 million in other operating expense, net) plus $155 million of incremental charges in Q4, totaling $881 million; included $515 million of non-cash impairments ($409 million intangible assets, $58 million inventory write-downs). Accruals of $82 million (other accrued expenses) and $152 million (other liabilities) at April 29, 2022 for ongoing patient support and other obligations. Employee headcount impact not disclosed.
2022-04-29divestiture_reductionannounced2022-05-252023GlobalMedical Surgical — Respiratory, Gastrointestinal, and Renal division (Renal Care Solutions business)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Subsequent event: definitive agreement with DaVita Inc. to form a new independent kidney care-focused medical device company (NewCo) with equal equity ownership; Medtronic contributing its entire Renal Care Solutions business (fiscal 2022 revenue of $325 million). Expected to close in calendar year 2023 subject to regulatory approvals. Employee headcount affected not disclosed; Medtronic separately expects a $60–90 million non-cash pre-tax goodwill impairment in the quarter ending July 29, 2022.
2022-04-29restructuringin_progress2023-04-28GlobalAll segmentsUSD 259 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program announced in Q3 fiscal year 2018; announcement date not specified. FY2022 net charges of $259M; $1.6B incurred since inception; company estimates about $1.8B total by end of fiscal year 2023. Employees affected not disclosed.
2022-04-29restructuringin_progress2023-04-28GlobalAll segmentsUSD 82 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program initiated in Q1 fiscal year 2021; announcement date not specified. FY2022 net charges of $82M; $349M incurred since inception; estimate of about $450M total by end of fiscal year 2023. Employees affected not disclosed.
2022-04-29othercompleted2021-06-03GlobalCardiovascular — Mechanical Circulatory SupportUSD 881 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Decision to stop distribution and sale of the Medtronic HVAD System; $726M charged in Q1 FY2022 plus $155M in Q4 FY2022. Includes $515M non-cash impairments and write-downs plus commitments, restructuring and patient support obligations. Headcount impact not disclosed.
2022-04-29acquisition_additionin_progress2022-01-10GlobalCardiovascularMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Affera for $925M including up to $250M contingent consideration; pending antitrust clearance and closing conditions. Headcount not disclosed.
2022-04-29acquisition_additioncompleted2022-05-132022-05-13GlobalNeurosciencesubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed after fiscal year end for approximately $1.2B ($28.25 per share). Purchase price allocation incomplete at filing; headcount not disclosed.
2022-04-29divestiture_reductionannounced2022-05-25GlobalMedical Surgical — Renal Care Solutionssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced after fiscal year end: contribution of the entire Renal Care Solutions business ($325M FY2022 revenue) to a new equally owned kidney care device company with DaVita; expected to close in calendar year 2023. Company expects a $60M-$90M non-cash goodwill impairment in the quarter ending July 29, 2022. Headcount not disclosed.
2022-04-29restructuringin_progress2018-08-012023-04-30GlobalAll SegmentsUSD 259 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Enterprise Excellence program. $259 million net charges recognized in FY2022. Program expected to conclude by end of FY2023.
2022-04-29restructuringin_progress2021-02-012023-04-30GlobalAll SegmentsUSD 82 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Simplification program. $82 million net charges recognized in FY2022. Program expected to conclude by end of FY2023.
2022-04-29restructuringcompleted2021-06-03GlobalCardiovascularUSD 726 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Decision to stop distribution and sale of Medtronic HVAD System. $726 million charges recorded in Q1 FY2022.
2022-04-29restructuringin_progress2018-07-012023-04-30GlobalAll segmentsUSD 259 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Fiscal 2022 net charges of $259 million. Program estimated to complete by end of fiscal 2023.
2022-04-29restructuringin_progress2021-05-012023-04-30GlobalAll segmentsUSD 82 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Fiscal 2022 net charges of $82 million. Program estimated to complete by end of fiscal 2023.
2022-04-29voluntary_separationcompleted2021-05-012022-04-29United StatesAll segmentsUSD 97 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Voluntary early retirement packages accepted in fiscal 2021, resulting in $97 million incremental defined benefit pension and post-retirement expenses recognized in fiscal 2021. Included in Simplification program context.
2022-04-29restructuringin_progressEmployee Severance [Member]USD 80,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-04-29restructuringin_progressAssociated Costs [Member]USD 274,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-04-29restructuringin_progressAsset Write-downs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-04-29restructuringin_progressOther Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-04-29restructuringin_progressUSD 354,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-01-28restructuringin_progress2017-11-012022-04-29All segmentsUSD 65 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Three-month net charges of $65 million under the Enterprise Excellence program; no employee count disclosed. Majority of remaining estimated charges expected by end of fiscal 2022.
2022-01-28restructuringin_progress2020-08-012022-04-29All segmentsUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Three-month net charges of $15 million under the Simplification program; no employee count disclosed. Majority of remaining estimated charges expected by end of fiscal 2022.
2022-01-28restructuringcompleted2021-06-03Cardiovascular — Mechanical Circulatory Support (HVAD System)USD 726 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Decision to stop distribution and sale of the Medtronic HVAD System; charges included $515 million of non-cash impairments and $211 million for commitments and obligations including restructuring and customer support obligations. No employee count disclosed.
2022-01-28restructuringin_progress2017-10-012022-04-29GlobalAll segmentsUSD 201 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month charges of $201M; $1.5B incurred since inception; total estimated $1.6B–$1.8B. No employee count disclosed.
2022-01-28restructuringin_progress2020-05-012022-04-29GlobalAll segmentsUSD 39 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month charges of $39M; $307M incurred since inception; total estimated $400M–$450M. No employee count disclosed.
2022-01-28restructuringcompleted2021-06-03GlobalCardiovascular — Mechanical Circulatory Support (HVAD System)USD 726 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to stop HVAD distribution; $726M charges including $515M non-cash impairments and $211M commitments. No employee count disclosed.
2022-01-28restructuringin_progress2018-07-012022-04-30GlobalAll segmentsUSD 65 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program announced in Q3 FY2018. Majority of remaining estimated charges expected by end of fiscal year 2022. Employee count not disclosed for current period activity.
2022-01-28restructuringin_progress2020-07-012022-04-30GlobalAll segmentsUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in Q1 FY2021. Majority of remaining estimated charges expected by end of fiscal year 2022. Employee count not disclosed for current period activity.
2022-01-28restructuringcompleted2021-06-03GlobalCardiovascularUSD 726 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Decision to stop distribution and sale of Medtronic HVAD System. Charges recorded in Q1 FY2022 (ended July 30, 2021). Includes $515M impairments/write-downs and $211M commitments/obligations. Employee count not disclosed.
2022-01-28restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-01-28restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-01-28restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-01-28restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 175,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-01-28restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-01-28restructuringin_progressEnterprise Excellence [Member]USD 206,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-01-28restructuringin_progressEmployee Severance [Member] / Simplification Restructuring Program [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-01-28restructuringin_progressAssociated Costs [Member] / Simplification Restructuring Program [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-01-28restructuringin_progressSimplification Restructuring Program [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-29restructuringin_progress2022-04-29GlobalAll segmentsUSD 136 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Multi-year program announced in fiscal 2018 Q3; $1.4B incurred since inception against $1.6–1.8B total estimate; majority of remaining charges expected by end of fiscal 2022. No employee count disclosed.
2021-10-29restructuringin_progress2022-04-29GlobalAll segmentsUSD 29 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in fiscal 2021 Q1; $293M incurred since inception against $400–450M total estimate; majority of remaining charges expected by end of fiscal 2022. No employee count disclosed.
2021-10-29restructuringin_progress2021-06-03GlobalCardiovascular — Mechanical Circulatory Support (HVAD System)USD 726 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to stop distribution and sale of Medtronic HVAD System announced 2021-06-03; $726M total charges recorded in fiscal 2022 Q1 including $515M non-cash impairments and $211M for commitments/obligations. Company remains committed to ~4,000 implanted patients. No employee count disclosed.
2021-10-29restructuringin_progress2018-07-012022-04-30GlobalAll segmentsUSD 62 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2022 charges of $62M recognized. Program announced Q3 FY2018. Majority of remaining charges expected by end of FY2022.
2021-10-29restructuringin_progress2020-07-012022-04-30GlobalAll segmentsUSD 18 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2022 charges of $18M recognized. Program announced Q1 FY2021. Majority of remaining charges expected by end of FY2022.
2021-10-29restructuringcompleted2021-06-03GlobalCardiovascularUSD 726 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Decision to stop distribution/sale of HVAD System. Charges include $515M impairments/write-downs and $211M commitments/obligations. Recorded in Q1 FY2022.
2021-10-29restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-29restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-29restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-29restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 121,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-29restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-29restructuringin_progressEnterprise Excellence [Member]USD 138,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-29restructuringin_progressEmployee Severance [Member] / Simplification Restructuring Program [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-29restructuringin_progressAssociated Costs [Member] / Simplification Restructuring Program [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-10-29restructuringin_progressSimplification Restructuring Program [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-30restructuringin_progress2017-11-01All segmentsUSD 74 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Quarterly net charges of $74M for Enterprise Excellence program; $33M in cost of products sold and $30M in SG&A. No employee counts disclosed. Cumulative program costs $1.4B; estimated total $1.6B-$1.8B, majority by end of fiscal year 2022. Announcement date approximated to fiscal Q3 2018 program launch.
2021-07-30restructuringin_progress2020-05-01All segmentsUSD 7 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Quarterly net charges of $7M for Simplification program, all in SG&A. No employee counts disclosed. Cumulative program costs $274M; estimated total $400M-$450M, majority by end of fiscal year 2022. Announcement date approximated to fiscal Q1 2021 program initiation.
2021-07-30othercompleted2021-06-03Cardiovascular — Mechanical Circulatory Support (HVAD System)USD 726 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Decision to stop distribution and sale of the Medtronic HVAD System; charges include $515M non-cash impairments/write-downs and $211M for commitments and obligations including restructuring and patient support. Approximately 4,000 implanted patients to be supported. No employee counts disclosed.
2021-07-30restructuringin_progress2017-10-012022-04-30GlobalAll segmentsUSD 74 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Net charges recognized in the quarter; program announced in fiscal year 2018 third quarter. Cumulative pre-tax costs since inception of $1.4 billion against a total estimated program cost of $1.6–1.8 billion. Employee headcount affected not disclosed; approximately 40 percent of estimated charges relate to employee termination benefits. Majority of remaining charges expected by end of fiscal 2022.
2021-07-30restructuringin_progress2020-05-012022-04-30GlobalAll segmentsUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Net charges recognized in the quarter, all within SG&A expense; announced in fiscal year 2021 first quarter. Cumulative pre-tax costs since inception of $274 million against a total estimated program cost of $400–450 million. Employee headcount affected not disclosed; approximately three quarters of estimated charges relate to employee termination benefits. Roll-forward table in the same footnote shows gross charges of $10 million for the quarter.
2021-07-30restructuringin_progress2021-06-03GlobalCardiovascular — Mechanical Circulatory Support (HVAD System)USD 211 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision announced June 3, 2021 to stop distribution and sale of the Medtronic HVAD System. Total charges of $726 million recorded in the quarter, including $515 million of non-cash impairments and write-downs ($409 million intangible asset impairment, $58 million inventory write-down) and $211 million for commitments and obligations including patient support obligations, restructuring, and other associated costs. Employee headcount affected not disclosed. Accruals of $130 million in other accrued expenses and $41 million in other liabilities at quarter-end.
2021-07-30restructuringin_progress2018-09-01GlobalAll segmentsUSD 74 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program announced Q3 FY2018. Q1 FY2022 charges of $74M include $12M employee termination benefits. Total estimated costs $1.6B-$1.8B. Majority expected incurred by end of FY2022.
2021-07-30restructuringin_progress2021-01-01GlobalAll segmentsUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated Q1 FY2021. Q1 FY2022 charges of $7M recognized in SG&A. Total estimated costs $400M-$450M. Majority expected incurred by end of FY2022.
2021-07-30voluntary_separationcompleted2021-01-01United StatesAll segmentsUSD 97 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Voluntary early retirement packages offered to eligible U.S. employees as part of Simplification program. Incremental expense of $97M recognized in FY2021.
2021-07-30restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-30restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-30restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 63,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-30restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-30restructuringin_progressEnterprise Excellence [Member]USD 75,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-30restructuringin_progressEmployee Severance [Member] / Simplification Restructuring Program [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-30restructuringin_progressAssociated Costs [Member] / Simplification Restructuring Program [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-30restructuringin_progressSimplification Restructuring Program [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-04-30restructuringin_progress2022-04GlobalAll segments — global operations, functional optimization, and commercial optimization objectivesUSD 349 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year global program announced in the third quarter of fiscal year 2018 (exact date not disclosed). FY2021 net charges of $349 million: $52 million in restructuring charges, net; $128 million in cost of products sold; $169 million in SG&A. Total expected pre-tax program charges of approximately $1.6–1.8 billion, roughly 40% employee termination benefits, with cash outlays substantially complete by end of FY2023. No employee headcount disclosed.
2021-04-30restructuringin_progress20202022-04GlobalAll segments — reorganization into a portfolio-level structure with Operating UnitsUSD 268 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Initiated in the first quarter of fiscal year 2021 (calendar 2020); new operating model fully operational at the start of Q4 FY2021. FY2021 net charges of $268 million: $241 million in restructuring charges, net (including $97 million of voluntary early retirement pension/post-retirement expense) plus $27 million in SG&A. Expected total pre-tax costs of approximately $400–450 million and annual savings of approximately $450–475 million by end of FY2022. No employee headcount disclosed.
2021-04-30voluntary_separationcompleted2020United StatesEligible U.S. employeesUSD 97 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Voluntary early retirement packages offered to certain eligible U.S. employees under the Simplification program. FY2021 incremental expense of $97 million ($73 million U.S. pension, $11 million defined contribution, $11 million U.S. post-retirement, $2 million cash/administrative), which is a component included within the Simplification program's $268 million FY2021 net charges. Number of participants not disclosed.
2021-04-30otherannounced2021-06-03GlobalCardiovascular — Cardiac Rhythm & Heart Failure (Mechanical Circulatory Support / HVAD System)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Subsequent-event decision to stop distribution and sale of the Medtronic HVAD System. FY2021 HVAD revenue was $141 million; approximately 4,000 implanted patients will continue to be supported. Company expects a non-cash pre-tax long-lived asset impairment of $400–500 million (primarily intangible assets) in the quarter ending July 30, 2021, plus customer support, restructuring, and other associated charges (amounts not quantified). No workforce headcount impact disclosed; included as an announced business exit with expected restructuring charges.
2021-04-30restructuringin_progress2017-12-312022-04-30GlobalEnterprise-wide (global operations, functional optimization, commercial optimization)USD 349 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year Enterprise Excellence Program announced in Q3 fiscal year 2018; 349 is net charges recognized in fiscal year 2021 only (includes 52 in restructuring charges, net, 128 in cost of products sold and 169 in SG&A). Program total estimated at 1.6-1.8 billion pre-tax, majority of charges by end of fiscal year 2022. Announcement date is approximate (filer states 'third quarter of fiscal year 2018'). Employees affected not disclosed.
2021-04-30restructuringin_progress2020-07-312022-04-30GlobalEnterprise-wide (portfolio/operating-unit reorganization, Technology Development Centers, dedicated sales organizations)USD 268 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Simplification program initiated in Q1 fiscal year 2021; 268 is net charges recognized in fiscal year 2021 (includes 241 in restructuring charges, net, and 27 in SG&A; excludes 97 of incremental pension/post-retirement expense for early-retirement participants). Program total estimated at 400-450 million pre-tax with annual savings of 450-475 million. Announcement date approximate (filer states 'first quarter of fiscal year 2021'). Employees affected not disclosed.
2021-04-30voluntary_separationcompleted2020-04-252021-04-30United StatesEnterprise-wideUSD 97 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Voluntary early retirement packages offered to eligible U.S. employees under the Simplification program during fiscal year 2021; 97 million of incremental defined benefit pension and post-retirement expense (73 pension, 11 defined contribution, 11 post-retirement, 2 cash/admin). Number of participants not disclosed.
2021-04-30otherannounced2021-06-03GlobalCardiovascular — HVAD mechanical circulatory supportUSD 450 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Post-fiscal-year-end decision to stop distribution and sale of the Medtronic HVAD System. Filer expects a non-cash pre-tax long-lived asset impairment of 400-500 million (primarily intangibles) in the quarter ending 2021-07-30, plus charges for customer support obligations, restructuring and other associated costs; charge value shown is the midpoint of the disclosed range. FY2021 HVAD revenue was 141 million; approximately 4,000 implanted patients to be supported. Employees affected not disclosed.
2021-04-30restructuringin_progress2018-07-012022-04-30GlobalAll segmentsUSD 349 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Enterprise Excellence Program. Fiscal 2021 net charges of $349 million. Majority of costs expected to be incurred by end of fiscal 2022.
2021-04-30restructuringin_progress2021-01-012022-04-30GlobalAll segmentsUSD 268 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Simplification Program initiated in Q1 FY2021. Fiscal 2021 net charges of $268 million. Majority of costs expected to be incurred by end of fiscal 2022.
2021-04-30restructuringin_progress2018-07-012022-04-30GlobalEnterpriseUSD 349 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Multi-year program announced Q3 FY2018. FY2021 net charges of $349 million recognized. Employee termination benefits component was $52 million.
2021-04-30restructuringin_progress2020-05-012022-04-30GlobalEnterpriseUSD 268 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Program initiated Q1 FY2021. FY2021 net charges of $268 million recognized. Includes $97 million for voluntary early retirement packages.
2021-04-30restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 128,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-04-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 169,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-04-30restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 66,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-04-30restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 295,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-04-30restructuringin_progressAsset Write-downs [Member] / Enterprise Excellence [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-04-30restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-04-30restructuringin_progressEnterprise Excellence [Member]USD 365,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-04-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Simplification Restructuring Program [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-04-30restructuringin_progressEmployee Severance [Member] / Simplification Restructuring Program [Member]USD 147,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-04-30restructuringin_progressAssociated Costs [Member] / Simplification Restructuring Program [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-04-30restructuringin_progressSimplification Restructuring Program [Member]USD 174,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-01-29restructuringin_progress2017-10-012022-04-30GlobalAll segmentsUSD 77 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced Q3 FY2018; net charges of $77M in the quarter and $241M YTD; total program cost estimated at $1.6-$1.8 billion, majority by end of FY2022; roughly 40% of charges relate to employee termination benefits. No employee count disclosed.
2021-01-29restructuringin_progress2020-05-012022-04-30GlobalAll segmentsUSD 84 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program initiated Q1 FY2021; net charges of $84M in the quarter and $229M YTD; total program cost estimated at $400-$450 million, majority by end of FY2022; about three quarters of charges relate to employee termination benefits. No employee count disclosed.
2021-01-29voluntary_separationcompleted2020-05-01United StatesAll segmentsUSD 97 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Incremental defined benefit pension and post-retirement expense of $97M recognized in the nine months ended January 29, 2021 for U.S. employees accepting voluntary early retirement packages under the Simplification program; $80M related to U.S. pension benefits, $11M to defined contribution plans, $4M to U.S. post-retirement benefits, and $2M to cash payments and administrative fees. No employee count disclosed.
2021-01-29restructuringin_progress2022-04-30GlobalAll segmentsUSD 241 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced in Q3 of fiscal year 2018; exact announcement date not disclosed. Charge shown is net charges recognized in the nine months ended 2021-01-29 (includes amounts in restructuring charges net, cost of products sold, and SG&A). Total program estimated at $1.6B-$1.8B pre-tax, majority expected by end of fiscal year 2022; approximately 40% of estimated charges are employee termination benefits. No employee headcount affected is disclosed. Expected completion date reflects fiscal year 2022 end (fiscal years end late April).
2021-01-29restructuringin_progress2022-04-30GlobalAll segmentsUSD 229 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Initiated in Q1 of fiscal year 2021; exact announcement date not disclosed. Charge shown is net charges recognized in the nine months ended 2021-01-29, which per the filer includes $97M of incremental pension/post-retirement expense for voluntary early retirement participants (see separate record). Total program estimated at $400M-$450M pre-tax, majority expected by end of fiscal year 2022; approximately three quarters of estimated charges are employee termination benefits. No employee headcount affected is disclosed. Expected completion date reflects fiscal year 2022 end.
2021-01-29voluntary_separationin_progress2022-04-30United StatesEligible U.S. employees (functions not specified)USD 97 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Voluntary early retirement packages offered during fiscal year 2021 as part of the Simplification program. Charge is incremental defined benefit pension and post-retirement expense ($80M U.S. pension, $11M defined contribution, $4M post-retirement, $2M cash payments/admin fees) and is included within the Simplification program's $229M nine-month charge — do not add to the program total. Number of participating employees not disclosed.
2021-01-29restructuringin_progress2018-09-012022-04-30GlobalAll segmentsUSD 77 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program announced in Q3 FY2018. Charges for Q3 FY2021 include employee termination benefits and associated costs. Majority of costs expected by end of FY2022.
2021-01-29restructuringin_progress2020-07-012022-04-30GlobalAll segmentsUSD 84 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in Q1 FY2021. Charges for Q3 FY2021 include employee termination benefits. Includes $97M incremental pension/post-retirement expenses for voluntary early retirements in YTD.
2021-01-29restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-01-29restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-01-29restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-01-29restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 216,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-01-29restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-01-29restructuringin_progressEnterprise Excellence [Member]USD 247,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-01-29restructuringin_progressSelling, General and Administrative Expenses [Member] / Simplification Restructuring Program [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-01-29restructuringin_progressEmployee Severance [Member] / Simplification Restructuring Program [Member]USD 123,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-01-29restructuringin_progressAssociated Costs [Member] / Simplification Restructuring Program [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-01-29restructuringin_progressSimplification Restructuring Program [Member]USD 138,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-10-30restructuringin_progress2018-01-012022-04-30All segmentsUSD 90 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Three-month charges of $90 million under Enterprise Excellence program; approximately half of estimated $1.6-$1.8 billion total charges relate to employee termination benefits. No employee counts disclosed.
2020-10-30restructuringin_progress2020-04-252022-04-30All segmentsUSD 102 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Three-month charges of $102 million under Simplification program initiated in Q1 FY2021; approximately three quarters of estimated $400-$450 million total charges relate to employee termination benefits. No employee counts disclosed.
2020-10-30voluntary_separationin_progress2020-04-25United StatesUSD 97 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Voluntary early retirement packages offered to eligible U.S. employees as part of Simplification program; $97 million incremental expense, including $80 million U.S. pension benefits, $11 million defined contribution plans, $4 million post-retirement benefits, $2 million cash payments and administrative fees. Employee count not disclosed.
2020-10-30restructuringin_progress2017-10-012022-04-30GlobalAll segmentsUSD 169 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended Oct 30, 2020 charges of $169M; total program estimated at $1.6B–$1.8B pre-tax. No employee count disclosed. Approximately half of estimated charges relate to employee termination benefits.
2020-10-30restructuringin_progress2020-05-012022-04-30GlobalAll segmentsUSD 153 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended Oct 30, 2020 charges of $153M; total program estimated at $400M–$450M pre-tax. Includes voluntary early retirement packages for eligible U.S. employees ($97M incremental pension/post-retirement expense). No employee count disclosed.
2020-10-30voluntary_separationin_progress2020-05-01United StatesCorporate / enterpriseUSD 97 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Voluntary early retirement packages offered to certain eligible U.S. employees as part of Simplification program; $97M incremental expense ($80M U.S. pension, $11M defined contribution, $4M post-retirement, $2M cash/admin). No headcount disclosed.
2020-10-30restructuringin_progress2018-07-012022-09-30GlobalAll segmentsUSD 169 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program announced Q3 FY2018. Charges recognized for six months ended Oct 30, 2020 include employee termination benefits and associated costs. Majority of estimated $1.6B-$1.8B total charges expected by end of FY2022.
2020-10-30restructuringin_progress2020-04-252022-09-30GlobalAll segmentsUSD 153 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated Q1 FY2021. Charges for six months ended Oct 30, 2020 include $97M in incremental defined benefit pension/post-retirement expenses for voluntary early retirement packages. Total estimated charges $400M-$450M, majority expected by end of FY2022.
2020-10-30restructuringin_progressEnterprise Excellence [Member]USD 90,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-10-30restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-10-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 48,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-10-30restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-10-30restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 150,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-10-30restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-10-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Simplification Restructuring Program [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-10-30restructuringin_progressEmployee Severance [Member] / Simplification Restructuring Program [Member]USD 53,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-10-30restructuringin_progressAssociated Costs [Member] / Simplification Restructuring Program [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-10-30restructuringin_progressSimplification Restructuring Program [Member]USD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-07-31restructuringin_progress2017-112022-04-29GlobalAll segmentsUSD 79 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 FY2021 charges of $79M (net of $2M favorable accrual adjustments); program total estimated at $1.6-$1.8 billion pre-tax, majority by end of FY2022; roughly half relates to employee termination benefits
2020-07-31restructuringin_progress2020-04-252022-04-29GlobalAll segmentsUSD 51 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		New program initiated Q1 FY2021; $50M of the $51M charge relates to employee termination benefits; estimated total pre-tax costs of $400-$450 million, majority by end of FY2022; about three quarters relate to employee termination benefits
2020-07-31voluntary_separationannounced2020-07-31United StatesEligible U.S. employeesUSD 100 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Subsequent to quarter end, as part of Simplification program, company offered certain eligible U.S. employees voluntary early retirement packages; charge consists primarily of incremental pension and post-retirement costs, to be recognized in Q2 FY2021
2020-07-31restructuringin_progress2022-04-29GlobalAll segmentsUSD 79 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced in Q3 fiscal year 2018 (exact date not disclosed); $79M recognized in Q1 FY2021 less $2M accrual adjustments; total program estimated at $1.6B-$1.8B with majority of charges by end of FY2022; no employee count disclosed
2020-07-31restructuringin_progress2022-04-29GlobalAll segmentsUSD 51 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated during Q1 FY2021 (exact announcement date not disclosed); $51M recognized in Q1 FY2021; total program estimated at $400M-$450M with majority of charges by end of FY2022; no employee count disclosed
2020-07-31voluntary_separationannouncedUnited StatesEligible U.S. employeesUSD 100 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Voluntary early retirement packages offered subsequent to July 31, 2020 under the Simplification program; charge of approximately $100M, primarily incremental pension and post-retirement costs, to be recognized in Q2 FY2021; no employee count disclosed
2020-07-31restructuringin_progress2018-09-012022-04-30GlobalAll segmentsUSD 79 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program announced Q3 FY2018. Charges recognized in Q1 FY2021 include $27M in cost of products sold and $47M in SG&A. Total estimated charges $1.6B-$1.8B.
2020-07-31restructuringin_progress2020-04-252022-04-30GlobalAll segmentsUSD 51 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated Q1 FY2021. Charges recognized include $50M in restructuring charges (primarily employee termination benefits) and $1M in SG&A. Total estimated charges $400M-$450M.
2020-07-31voluntary_separationannounced2020-08-01United StatesEligible U.S. employeesUSD 100 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Subsequent to July 31, 2020, company offered voluntary early retirement packages to eligible U.S. employees as part of Simplification program. Expected charge of approx $100M primarily for incremental pension and post-retirement costs.
2020-07-31restructuringin_progressEnterprise Excellence [Member]USD 79,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-07-31restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-07-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-07-31restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-07-31restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 73,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-07-31restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-07-31restructuringin_progressSimplification Restructuring Program [Member]USD 51,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-07-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Simplification Restructuring Program [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-07-31restructuringin_progressEmployee Severance [Member] / Simplification Restructuring Program [Member]USD 50,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-07-31restructuringin_progressAssociated Costs [Member] / Simplification Restructuring Program [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-04-24restructuringin_progress2022-04-29GlobalAll segments (global operations, functional optimization, and commercial optimization objectives)USD 462 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year global program announced in the third quarter of fiscal 2018; exact announcement date not disclosed. Fiscal 2020 gross charges of $462 million (employee termination benefits $129 million, associated costs $300 million, asset write-downs $24 million, other $9 million), partially offset by $21 million of accrual adjustments; $427 million paid in cash during the year. Program-wide pre-tax charges estimated at $1.6–$1.8 billion, the vast majority to be incurred by end of fiscal 2022, with cash outlays substantially complete by end of fiscal 2023; roughly half of program charges relate to employee termination benefits. No employee headcount affected is disclosed.
2020-04-24otherannounced2020-04-242027-04-30United StatesU.S. employees participating in the qualified defined benefit pension planUSD 94 (millions)other
f5-10k / GLM-5.3-flash-HTML		Freeze of U.S. pension benefit accruals beginning in 2027: employees continue earning benefits until April 30, 2027, after which benefits shift to a defined contribution structure. The company recognized a $94 million curtailment benefit (a gain, not a charge) in fiscal 2020 as a result of this change. Affected employee count not disclosed.
2020-04-24restructuringin_progress20182022-04-30GlobalAll segmentsUSD 462 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year Enterprise Excellence Program announced in the third quarter of fiscal year 2018; figures reflect fiscal year 2020 activity only. FY2020 charges of $462M (including $129M employee termination benefits, $149M in cost of products sold, $165M in SG&A) were partially offset by $21M of accrual adjustments. Total program pre-tax charges estimated at $1.6B-$1.8B with charges largely incurred by end of FY2022 and cash outlays substantially complete by end of FY2023. Employees affected not disclosed.
2020-04-24acquisition_additioncompletedbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fiscal year 2020 business combinations with $612M acquisition-date fair value of net assets acquired (including $333M goodwill); headcount added through these acquisitions is not disclosed.
2020-04-24restructuringin_progress2018-01-012022-04-30GlobalAll segmentsUSD 462 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Enterprise Excellence Program. Fiscal 2020 charges of $462 million, partially offset by $21 million accrual adjustments. Majority of estimated charges expected by end of fiscal 2022.
2020-04-24restructuringin_progress2018-07-282022-04-29GlobalGlobal Operations, Functional Optimization, Commercial OptimizationUSD 462 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Enterprise Excellence Program announced in Q3 FY2018. FY2020 charges of $462M include $129M in employee termination benefits and $300M in associated costs. Program expected to result in pre-tax charges of $1.6B-$1.8B by end of FY2022.
2020-04-24restructuringin_progressEnterprise Excellence [Member]USD 462,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-04-24restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 155,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-04-24restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 168,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-04-24restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 129,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-04-24restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 300,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-04-24restructuringin_progressAsset Write-downs [Member] / Enterprise Excellence [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-04-24restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-01-24restructuringin_progress2017-08-012022-04-30GlobalAll segmentsUSD 97 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Multi-year program announced Q3 FY2018; total expected pre-tax charges of $1.6-$1.8 billion, roughly half for employee termination benefits, majority incurred by end of FY2022. Q3 FY2020 charges of $97 million ($13M in restructuring charges, net; $50M in cost of products sold; $34M in SG&A). No employee counts disclosed.
2020-01-24restructuringin_progress2017-08-012022-04-30GlobalAll segmentsUSD 328 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month FY2020 charges of $328 million ($87M restructuring charges, net; $117M cost of products sold; $111M SG&A; $6M asset write-downs; $13M accrual adjustments for employees finding internal positions). No employee counts disclosed.
2020-01-24restructuringin_progress2017-10-012022-04-30GlobalAll segmentsUSD 97 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Enterprise Excellence program; $97M charge in Q3 FY2020, $328M YTD. Total program estimated at $1.6–1.8B pre-tax. No employee count disclosed.
2020-01-24acquisition_additioncompletedGlobalMultiple segmentsUSD 272 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		FY2020 acquisitions with $272M net assets acquired; no headcount added disclosed. Includes Titan Spine acquisition in Restorative Therapies Group.
2020-01-24restructuringin_progress2018-10-012022-04-30GlobalAll segmentsUSD 97 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Enterprise Excellence program. Q3 2020 charges of $97M recognized. Total expected pre-tax costs $1.6B-$1.8B. Employee count affected not disclosed in this filing.
2020-01-24restructuringin_progress2018-10-012022-04-30GlobalAll segmentsUSD 328 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Enterprise Excellence program. YTD 2020 charges of $328M recognized. Includes $13M accrual adjustments for employees finding other positions.
2020-01-24restructuringin_progressEnterprise Excellence [Member]USD 97,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-01-24restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 50,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-01-24restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 34,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-01-24restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 91,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-01-24restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 223,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-01-24restructuringin_progressAsset Write-downs [Member] / Enterprise Excellence [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-01-24restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-10-25restructuringin_progress2018-01-012022-04-01GlobalAll segmentsUSD 95 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced in Q3 fiscal 2018; approximately half of estimated $1.6-$1.8 billion total charges relate to employee termination benefits, majority expected by end of fiscal 2022. Quarterly charge of $95 million recognized in Q2 FY2020; no employee count disclosed.
2019-10-25restructuringin_progress2018-01-012022-04-01GlobalAll segmentsUSD 231 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Year-to-date charges of $231 million for the six months ended October 25, 2019 under the Enterprise Excellence restructuring program; no employee count disclosed.
2019-10-25restructuringin_progress2017-10-012022-04-30GlobalAll segmentsUSD 231 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six-month charges of $231M; program estimated at $1.6B–$1.8B total pre-tax, majority by end of FY2022. Approximately half relates to employee termination benefits. No employee headcount affected disclosed.
2019-10-25restructuringin_progress2018-07-282022-04-30GlobalAll segmentsUSD 231 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Enterprise Excellence program. YTD charges of $231M include $79M employee termination benefits and $139M associated costs. Approx half of total estimated $1.6B-$1.8B charges are employee termination benefits.
2019-10-25restructuringin_progressEnterprise Excellence [Member]USD 95,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-10-25restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-10-25restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-10-25restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 79,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-10-25restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 139,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-10-25restructuringin_progressAsset Write-downs [Member] / Enterprise Excellence [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-10-25restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-07-26restructuringin_progress2018-01-012022-04-30GlobalAll segmentsUSD 136 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 FY2020 charges of $136M, partially offset by $12M accrual adjustments for employees finding other positions within Medtronic; program total estimated at $1.6-$1.8 billion pre-tax, majority by end of fiscal 2022; approximately half related to employee termination benefits. No employee counts disclosed in the quarter.
2019-07-26restructuringin_progressGlobalAll segmentsUSD 136 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in fiscal year 2018 Q3; no employee-affected count disclosed. Q1 FY2020 charges of $136M were partly offset by $12M of accrual adjustments for employees finding other positions. Estimated program total of $1.6B-$1.8B pre-tax, majority of charges expected by end of fiscal year 2022; roughly half of estimated charges relate to employee termination benefits.
2019-07-26restructuringin_progress2018-10-012022-04-30GlobalAll segmentsUSD 136 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Enterprise Excellence program. Q1 FY20 charges of $136M recognized, partially offset by $12M accrual adjustments for employees finding other positions. Total program estimated at $1.6B-$1.8B pre-tax.
2019-07-26restructuringin_progressEnterprise Excellence [Member]USD 136,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-07-26restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-07-26restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 42,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-07-26restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 52,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-07-26restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 71,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-07-26restructuringin_progressAsset Write-downs [Member] / Enterprise Excellence [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-07-26restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-04-26restructuringin_progress2022-04-29GlobalAll segmentsUSD 424 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year global Enterprise Excellence Program announced in the third quarter of fiscal 2018 (quarter ended January 26, 2018). Fiscal 2019 charges of $424 million included $192 million of employee termination benefits; fiscal 2019 cash payments totaled $314 million, leaving a $122 million accrual at year-end. Program-wide expected pre-tax charges of $1.6–$1.8 billion, roughly half for employee termination benefits, with the vast majority of charges expected by end of fiscal 2022 (April 29, 2022) and cash outlays substantially complete by end of fiscal 2023 (April 28, 2023). Number of employees affected was not disclosed.
2019-04-26acquisition_additioncompleted2018-12-18Restorative Therapies Groupbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Robotic guidance systems maker acquired December 18, 2018 (date shown is the acquisition completion date) for total consideration of $1.6 billion net of cash acquired; goodwill partly attributed to an assembled workforce, but the number of employees added was not disclosed.
2019-04-26acquisition_additioncompleted2019-03-08Cardiac and Vascular Groupbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Cardiac ablation company acquired March 8, 2019 (date shown is the acquisition completion date) for $316 million net of cash acquired, including $100 million of contingent consideration; employee headcount added was not disclosed.
2019-04-26restructuringin_progressGlobalAll segments (global operations, functional optimization, commercial optimization)USD 424 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced in the third quarter of fiscal year 2018; exact announcement date not disclosed. FY2019 charges of $424M comprise $192M employee termination benefits, $193M associated costs, $17M asset write-downs and $22M other costs; $198M was recognized in the restructuring charges, net income-statement line, with the remainder in cost of products sold and SG&A. Multi-year program: estimated $1.6B-$1.8B pre-tax charges, majority expected by end of fiscal year 2022, cash outlays substantially complete by end of fiscal year 2023; approximately half of estimated charges relate to employee termination benefits. Employees affected not disclosed.
2019-04-26restructuringcompletedGlobalAll segments (Covidien integration cost synergies)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program achieved in the third quarter of fiscal year 2018 and completed; no new charges in fiscal year 2019. FY2019 activity consisted of $17M of accrual adjustments reflecting employees finding other positions, cancelled terminations and lower-than-estimated benefits. Employees affected not disclosed.
2019-04-26acquisition_additioncompleted2018-12-182018-12-18Restorative Therapies Groupbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Robotic guidance systems company acquired December 18, 2018; total consideration net of cash acquired of $1.6 billion. Headcount added not disclosed.
2019-04-26acquisition_additioncompleted2019-03-082019-03-08Cardiac and Vascular Groupbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cardiac ablation device company acquired March 8, 2019; total consideration net of cash acquired of $316 million ($216M cash and $100M contingent consideration). Headcount added not disclosed.
2019-04-26othercompletedGlobalCardiac and Vascular Group; Restorative Therapies GroupUSD 149 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2019 charges of $149M associated with business exits, primarily intangible asset impairments, including $61M in the Cardiac and Vascular Group and $26M in the Restorative Therapies Group. Headcount impact not disclosed.
2019-04-26restructuringin_progress2018-07-292022-04-30GlobalAll segmentsUSD 424 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Enterprise Excellence Program announced Q3 FY2018. FY2019 charges include $198M in restructuring charges, net, $91M in cost of products sold, and $118M in SG&A. Total estimated pre-tax charges $1.6B-$1.8B.
2019-04-26divestiture_reductioncompleted2017-07-292017-07-29GlobalMinimally Invasive Therapies GroupItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Divestiture of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses completed July 29, 2017. Employee count not explicitly disclosed for this action.
2019-04-26restructuringin_progress2018-07-272022-04-29GlobalAll segmentsUSD 424 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Enterprise Excellence Program announced in Q3 FY2018. FY2019 charges of $424 million include $198 million in restructuring charges net, $91 million in cost of products sold, and $118 million in SG&A. Employee termination benefits are approximately half of estimated total charges. Specific employee count not disclosed.
2019-04-26voluntary_separationcompleted2017-01-012017-12-31United StatesAll segmentsUSD 73 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Voluntary early retirement packages offered to eligible U.S. employees in FY2017. $73 million incremental defined benefit pension and post-retirement related expenses recognized in FY2017. No new charges in FY2019, but accrual adjustments of $17 million recognized in FY2019 related to prior program.
2019-04-26restructuringin_progressEnterprise Excellence [Member]USD 424,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-04-26restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 91,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-04-26restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 118,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-04-26restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 192,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-04-26restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 193,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-04-26restructuringin_progressAsset Write-downs [Member] / Enterprise Excellence [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-04-26restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-04-26restructuringin_progressCost Synergies Initiative [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-01-25restructuringin_progress2017-112022-04-26All segmentsUSD 69 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced in Q3 fiscal 2018; total expected pre-tax charges of $1.6-$1.8 billion, majority by end of fiscal 2022, with roughly half related to employee termination benefits. Q3 FY2019 charge of $69 million includes $21 million in cost of products sold and $19 million in SG&A; nine-month charge was $264 million. No specific employee counts disclosed in this filing.
2019-01-25restructuringin_progress2022-04-30GlobalAll segmentsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in fiscal year 2018 Q3; estimated pre-tax charges of $1.6 billion to $1.8 billion, majority expected by end of fiscal year 2022, cash outlays substantially complete by end of fiscal year 2023. Approximately half of estimated charges relate to employee termination benefits. No employee headcount affected is disclosed. Charges recognized in the three and nine months ended January 25, 2019 were $69 million and $264 million, respectively.
2019-01-25acquisition_additioncompletedGlobalRestorative Therapies Groupbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Mazor Robotics completed December 18, 2018; total consideration net of cash acquired was $1.6 billion. Headcount added through the acquisition is not disclosed. $51 million of acquisition-related costs recognized in the three and nine months ended January 25, 2019.
2019-01-25restructuringin_progress2018-07-282022-04-29GlobalAll segmentsUSD 69 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Enterprise Excellence program. Q3 2019 charges of $69M include $21M in COGS and $19M in SG&A. Total expected charges $1.6B-$1.8B by end of FY2022. Employee count not disclosed.
2019-01-25restructuringcompleted2018-07-28GlobalAll segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost Synergies program related to Covidien acquisition. Completed in Q3 FY2018. Q3 2019 recognized $1M in accrual adjustments. No new charges.
2019-01-25restructuringin_progressCost of Sales [Member] / Enterprise Excellence [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-01-25restructuringin_progressSelling, General and Administrative Expenses [Member] / Enterprise Excellence [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-01-25restructuringin_progressEnterprise Excellence [Member]USD 69,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-01-25restructuringin_progressAsset Write-downs [Member] / Enterprise Excellence [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-01-25restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 131,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-01-25restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 107,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-01-25restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-10-26restructuringin_progress2018-01-012022-04-30GlobalAll segmentsUSD 75 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced Q3 FY2018; total expected pre-tax charges of $1.6-$1.8 billion, majority incurred by end of FY2022; approximately half related to employee termination benefits. Q2 FY2019 charge of $75 million; six-month charge of $195 million. No employee counts disclosed.
2018-10-26restructuringin_progress2017-10-012022-04-30GlobalAll segmentsUSD 1,600 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in Q3 FY2018; estimated $1.6B–$1.8B pre-tax charges, majority by end of FY2022. Approximately half relates to employee termination benefits. No employee headcount disclosed. $195M in charges recognized in six months ended October 26, 2018.
2018-10-26divestiture_reductioncompleted2017-07-292017-07-29GlobalMinimally Invasive Therapies Groupother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health included 17 dedicated manufacturing sites; no employee headcount disclosed. Prior-period event, included for context only.
2018-10-26acquisition_additionannounced2018-09-012019-01-31GlobalRestorative Therapies Group (Spine)USD 1,600 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Intention to acquire Mazor Robotics for approximately $1.6 billion ($1.3B net of existing stake and cash acquired), announced September 2018, expected to close Q3 FY2019. No headcount disclosed.
2018-10-26restructuringin_progress2018-01-012022-04-30GlobalAll segmentsUSD 195 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program announced in Q3 FY2018. Charges for six months ended Oct 26, 2018 include $78M employee termination benefits, $91M associated costs, $13M asset write-downs, and $13M other costs. Total estimated charges $1.6B-$1.8B by end of FY2022. Employee count not disclosed.
2018-10-26restructuringcompleted2015-01-012018-07-28GlobalAll segmentsUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program related to Covidien integration completed in Q3 FY2018. No new charges recognized in current period; only accrual adjustments of $7M for six months ended Oct 26, 2018. Employee count not disclosed.
2018-10-26restructuringin_progressCost of Sales [Member] / Associated Costs [Member] / Enterprise Excellence [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-10-26restructuringin_progressSelling, General and Administrative Expenses [Member] / Associated Costs [Member] / Enterprise Excellence [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-10-26restructuringin_progressCost Synergies Initiative [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-10-26restructuringin_progressEnterprise Excellence [Member]USD 75,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-10-26restructuringin_progressAsset Write-downs [Member] / Enterprise Excellence [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-10-26restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 91,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-10-26restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 78,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-10-26restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-27restructuringin_progress2022-04-30All segmentsUSD 120 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Enterprise Excellence program announced in Q3 fiscal 2018; approximately half of estimated $1.6-$1.8 billion total charges relate to employee termination benefits, but no employee counts disclosed. Q1 FY2019 charges of $120 million partially offset by $2 million accrual adjustments; charges include $69 million in restructuring charges, net (primarily employee termination benefits), $15 million in cost of products sold, $23 million in SG&A, and $13 million of fixed asset write-downs in SG&A. Majority of charges expected by end of fiscal 2022.
2018-07-27restructuringcompletedAdministrative office optimization, manufacturing and supply chain infrastructure, and general and administrative savingsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Covidien integration cost synergies program completed in Q3 fiscal 2018 with $850 million in cost synergies achieved. No charges recognized in Q1 FY2019; accrual adjustments of $5 million recorded. No employee counts disclosed.
2018-07-27divestiture_reductioncompleted2017-07-29Minimally Invasive Therapies GroupMD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Divestiture of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health completed July 29, 2017; divested businesses had net sales of $0.6 billion in the prior-year quarter. No headcount figures disclosed.
2018-07-27restructuringin_progress2022-04-30GlobalAll segmentsUSD 120 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced in fiscal Q3 2018 (exact date not stated); program estimated at $1.6B-$1.8B pre-tax charges, majority by end of FY2022, about half employee termination benefits. Q1 FY2019 charges were $120M (incl. $66M employee termination benefits, $38M associated costs, $13M asset write-downs, $3M other), offset by $2M accrual adjustments; no employee count disclosed. Termination-benefit accrual was $74M at 2018-07-27.
2018-07-27restructuringcompletedGlobalAll segmentsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Covidien integration cost-synergy program completed in fiscal Q3 2018; no charges recognized in Q1 FY2019, only $5M of accrual adjustments; remaining accrual $105M at 2018-07-27. No employee count disclosed.
2018-07-27otherin_progressNot specifiedCardiac and Vascular GroupUSD 80 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Exit of a business within the Cardiac and Vascular Group recognized in Q1 FY2019, primarily $61M of definite-lived intangible asset charges; no headcount impact disclosed.
2018-07-27restructuringin_progress2018-01-012022-04-30GlobalAll segmentsUSD 120 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program announced in Q3 FY2018. Q2 FY2019 charges of $120M include $66M employee termination benefits, $38M associated costs, $13M asset write-downs, and $3M other costs. Partially offset by $2M accrual adjustments for employees finding other positions. Total expected pre-tax charges $1.6B-$1.8B by end of FY2022.
2018-07-27restructuringcompleted2018-04-27GlobalAll segmentsUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program related to Covidien integration completed in Q3 FY2018. No charges recognized in Q2 FY2019; $5M accrual adjustments recognized for employees finding other positions or cancellations.
2018-07-27restructuringin_progressCost of Sales [Member] / Associated Costs [Member] / Enterprise Excellence [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-27restructuringin_progressSelling, General and Administrative Expenses [Member] / Associated Costs [Member] / Enterprise Excellence [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-27restructuringin_progressAsset Write-downs [Member] / Enterprise Excellence [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-27restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-27restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 66,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-27restructuringin_progressOther Restructuring [Member] / Enterprise Excellence [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-27restructuringin_progressCost Synergies Initiative [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-07-27restructuringin_progressEnterprise Excellence [Member]USD 120,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-04-27restructuringin_progress2017-102023-04GlobalAll segmentsUSD 96 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year global program announced in Q3 FY2018 (quarter ran Oct 28, 2017 – Jan 26, 2018; announcement month approximate). FY2018 charges of $96M comprise $35M employee termination benefits and $61M associated costs ($28M in cost of products sold, $33M in SG&A). Expected program pre-tax charges total $1.6B–$1.8B, roughly half for employee terminations; vast majority of charges by end of FY2022, cash outlays substantially complete by end of FY2023; targets more than $3.0B annual gross savings by end of FY2022. Employee count not disclosed.
2018-04-27restructuringcompleted2015-012019-04All segmentsUSD 45 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Covidien integration cost-synergy program; $850M of synergies achieved and program completed in Q3 FY2018. FY2018 charges of $45M (including $29M employee termination and contract termination costs; $12M in cost of products sold; $4M in SG&A), partially offset by $34M accrual adjustments. Cash outlays scheduled to be substantially complete by end of FY2019. Employee count not disclosed. Announcement date reflects Covidien acquisition close (January 26, 2015); no separate program announcement date given.
2018-04-27divestiture_reductioncompleted2017-042017-07-29Minimally Invasive Therapies Groupdiscontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Sale of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health closed July 29, 2017 for $6.1B proceeds ($697M pre-tax gain); disclosed in a dedicated divestiture footnote (did not qualify as discontinued operations). Employee headcount transferred not disclosed; divestiture included 17 dedicated manufacturing sites, and employees transferred with the business (evidenced by $16M accelerated stock compensation for transferring employees). Definitive agreement entered April 2017.
2018-04-27restructuringin_progress2022-04-29GlobalAll segments — global operations, functional optimization, commercial optimizationUSD 96 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced in the third quarter of fiscal year 2018 (exact date not disclosed). FY2018 charges of $96M comprise $35M employee termination benefits in restructuring charges, net, plus $61M associated costs ($28M in cost of products sold, $33M in SG&A). Multi-year program: total pre-tax charges estimated at $1.6B-$1.8B with expected annual gross savings exceeding $3.0B by end of fiscal 2022; approximately half of estimated charges relate to employee termination benefits. Employees affected not disclosed.
2018-04-27restructuringcompletedGlobalAll segments — Covidien integration cost synergies (administrative office optimization, manufacturing and supply chain infrastructure, G&A)USD 45 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program achieved $850M in cost synergies and was completed in the third quarter of fiscal year 2018; cash outlays substantially complete by end of fiscal 2019. FY2018 charges of $45M were partially offset by $34M of accrual adjustments (employees redeployed, cancellations, lower-than-estimated benefits). Employees affected not disclosed; program spans multiple prior fiscal years, only FY2018 activity captured.
2018-04-27divestiture_reductioncompleted2017-04-012017-07-29GlobalMinimally Invasive Therapies Group — Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businessesUSD 114 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement entered in April 2017 (exact date not disclosed); divestiture to Cardinal Health completed July 29, 2017. Employees transferred with the divestiture (count not disclosed); $16M of the $114M FY2018 divestiture-related charges was accelerated stock compensation for transferring employees. Transaction included 17 dedicated manufacturing sites; $697M pre-tax gain recognized in FY2018.
2018-04-27restructuringin_progress2017-10-012022-04-30GlobalAll segmentsUSD 96 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Enterprise Excellence Program announced in Q3 FY2018. Expected pre-tax charges of $1.6B-$1.8B total. Approximately half related to employee termination benefits. FY2018 charges of $96M recognized ($35M termination benefits, $61M associated costs).
2018-04-27restructuringcompleted2015-01-262018-04-27GlobalAll segmentsUSD 45 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Cost synergies related to Covidien acquisition achieved in Q3 FY2018. FY2018 charges of $45M recognized, partially offset by $34M accrual adjustments.
2018-04-27voluntary_separationcompleted2017-01-012017-12-31United StatesAll segmentsUSD 73 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Voluntary early retirement packages offered to eligible U.S. employees in FY2017. Incremental expenses of $73M recognized in FY2017.
2018-04-27restructuringin_progress2018-01-272022-04-29GlobalAll segmentsUSD 1,600 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Enterprise Excellence Program announced in Q3 FY2018. Estimated pre-tax charges of $1.6B-$1.8B, majority incurred by end of FY2022. Approximately half related to employee termination benefits. No specific headcount disclosed.
2018-04-27restructuringcompleted2015-01-262018-04-27GlobalAll segmentsUSD 45 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Cost Synergies related to Covidien acquisition. Program achieved in Q3 FY2018. FY2018 charges of $45M partially offset by $34M accrual adjustments. No specific headcount disclosed.
2018-04-27divestiture_reductioncompleted2017-04-012017-07-29GlobalMinimally Invasive Therapies GroupUSD 114 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Divestiture of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses. Includes 16M accelerated stock comp for transferring employees. No specific headcount disclosed.
2018-04-27restructuringin_progressCost of Sales [Member] / Associated Costs [Member] / Enterprise Excellence [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-04-27restructuringin_progressCost of Sales [Member] / Cost Synergies Initiative [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-04-27restructuringin_progressSelling, General and Administrative Expenses [Member] / Associated Costs [Member] / Enterprise Excellence [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-04-27restructuringin_progressSelling, General and Administrative Expenses [Member] / Cost Synergies Initiative [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-04-27restructuringin_progressAsset Write-downs [Member] / Cost Synergies Initiative [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-04-27restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 61,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-04-27restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-04-27restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-04-27restructuringin_progressOther Restructuring [Member] / Cost Synergies Initiative [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-04-27restructuringin_progressCost Synergies Initiative [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-04-27restructuringin_progressEnterprise Excellence [Member]USD 96,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-01-26restructuringin_progress2017-10-282022-04-29All reportable segmentsUSD 32 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Enterprise Excellence program announced in Q3 FY2018; expected total pre-tax charges of $1.6-$1.8 billion, majority by end of fiscal 2022; approximately half related to employee termination benefits. Charges recognized in restructuring charges, net, cost of products sold, and SG&A.
2018-01-26restructuringcompleted2018-01-26All reportable segmentsUSD 45 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cost synergies program related to administrative office optimization, manufacturing and supply chain infrastructure, and G&A savings completed in Q3 FY2018; $45 million of charges recognized in the nine months ended January 26, 2018.
2018-01-26divestiture_reductioncompleted2017-04-012017-07-29Minimally Invasive Therapies GroupUSD 114 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health completed July 29, 2017; included 17 dedicated manufacturing sites; employees transferred with the divestiture received accelerated stock compensation ($16 million); no headcount figure disclosed.
2018-01-26restructuringin_progress2017-10-272022-04-29GlobalAll reportable segmentsUSD 32 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Enterprise Excellence program announced in Q3 FY2018; total estimated pre-tax charges of $1.6–1.8 billion through FY2022. Approximately half relates to employee termination benefits. No employee count disclosed. $32M charged in Q3; $9M employee termination benefits and $23M associated costs YTD.
2018-01-26restructuringcompleted2017-10-27GlobalAll reportable segmentsUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Covidien cost synergies program completed in Q3 FY2018; $45M in charges recognized YTD ($25M employee termination benefits, $20M other costs). No employee count disclosed.
2018-01-26divestiture_reductioncompleted2017-04-012017-07-29GlobalMinimally Invasive Therapies GroupUSD 114 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health completed 2017-07-29 for $6.1B. Divestiture-related items of $114M YTD include professional fees and $16M accelerated stock compensation for transferring employees. No headcount transferred disclosed.
2018-01-26restructuringin_progress2017-10-282022-04-29GlobalAll reportable segmentsUSD 32 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced in Q3 FY2018. Total expected pre-tax charges $1.6B-$1.8B. Q3 charges of $32M included $9M employee termination benefits and $23M associated costs (salaries, consulting). Majority of charges expected by end of FY2022.
2018-01-26restructuringcompleted2018-01-26GlobalAll reportable segmentsUSD 45 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program completed in Q3 FY2018. YTD charges of $45M included $25M employee termination benefits and $20M other costs. Accrual adjustments of $15M recognized.
2018-01-26divestiture_reductioncompleted2017-04-292017-07-29GlobalMinimally Invasive Therapies GroupUSD 114 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health completed July 29, 2017. YTD divestiture-related items expense of $114M included professional fees and $16M accelerated stock compensation for transferring employees.
2018-01-26restructuringin_progressCost of Sales [Member] / Associated Costs [Member] / Enterprise Excellence [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-01-26restructuringin_progressSelling, General and Administrative Expenses [Member] / Associated Costs [Member] / Enterprise Excellence [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-01-26restructuringin_progressCost Synergies Initiative [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-01-26restructuringin_progressEnterprise Excellence [Member]USD 32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-01-26restructuringin_progressCost of Sales [Member] / Cost Synergies Initiative [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-01-26restructuringin_progressSelling, General and Administrative Expenses [Member] / Cost Synergies Initiative [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-01-26restructuringin_progressAssociated Costs [Member] / Enterprise Excellence [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-01-26restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-01-26restructuringin_progressEmployee Severance [Member] / Enterprise Excellence [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-01-26restructuringin_progressOther Restructuring [Member] / Cost Synergies Initiative [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-10-27restructuringin_progress2019-04-26All reportable segmentsUSD 26 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Covidien integration cost synergies program; charges primarily employee termination costs and manufacturing/facility closure costs. Cash outlays substantially complete by end of fiscal year 2019. Restructuring reserve of $212 million at October 27, 2017.
2017-10-27divestiture_reductioncompleted2017-04-012017-07-29Minimally Invasive Therapies GroupUSD 67 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health completed July 29, 2017; included 17 dedicated manufacturing sites transferred. Employees transferring with the divestiture received accelerated stock compensation ($16 million YTD). No headcount figure disclosed.
2017-10-27restructuringin_progress2015-04-24GlobalAll reportable segmentsUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Gross charges of $45M for six months ended 2017-10-27 (net $16M after $13M accrual adjustments). Employee termination cost accrual was $212M at quarter-end. Cash outlays scheduled to be substantially complete by end of fiscal year 2019. No employee headcount affected disclosed.
2017-10-27divestiture_reductioncompleted2017-04-012017-07-29GlobalMinimally Invasive Therapies Group — Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businessesUSD 114 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale to Cardinal Health completed 2017-07-29 for $6.1B proceeds. Divestiture-related expenses of $114M for six months (including $16M accelerated stock comp for transferring employees). Included 17 dedicated manufacturing sites. No employee headcount impact disclosed.
2017-10-27restructuringin_progress2019-04-27GlobalAll segmentsUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost synergies initiative related to Covidien integration. Charges primarily for employee termination costs and facility closures. Cash outlays expected substantially complete by end of fiscal 2019.
2017-10-27restructuringin_progress2019-04-27GlobalAll segmentsUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD Cost synergies initiative charges. Includes accrual adjustments for employees finding other positions.
2017-10-27divestiture_reductioncompleted2017-04-012017-07-29GlobalMinimally Invasive Therapies GroupUSD 67 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Sale of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health. Expenses primarily for professional services. No specific headcount disclosed.
2017-10-27divestiture_reductioncompleted2017-04-012017-07-29GlobalMinimally Invasive Therapies GroupUSD 114 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		YTD divestiture-related items. Includes $16 million accelerated stock compensation for employees transferring with divestiture.
2017-10-27restructuringin_progressCost of Sales [Member] / Cost Synergies Initiative [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-10-27restructuringin_progressSelling, General and Administrative Expenses [Member] / Cost Synergies Initiative [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-10-27restructuringin_progressCost Synergies Initiative [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-10-27restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-10-27restructuringin_progressOther Restructuring [Member] / Cost Synergies Initiative [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-28restructuringin_progress2019-04-26All reportable segmentsUSD 19 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Covidien integration cost synergies program; $19M charges in the quarter partially offset by $5M accrual adjustments; restructuring accrual of $257M at quarter-end; cash outlays substantially complete by end of fiscal 2019. No employee counts disclosed.
2017-07-28divestiture_reductioncompleted2017-04-012017-07-29Minimally Invasive Therapies Group — Patient Monitoring & Recovery divisionUSD 47 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health for $6.1 billion, completed July 29, 2017; included 17 dedicated manufacturing sites. No employee headcount disclosed. Divestiture-related items expense of $47M in the quarter included $22M legal/advisory and $16M accelerated stock compensation.
2017-07-28restructuringin_progress2019-04-30GlobalAll reportable segmentsUSD 19 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Covidien integration cost synergies program; $19M in charges recognized in Q1 FY2018, partially offset by $5M accrual adjustments; restructuring accrual of $257M at quarter-end. Cash outlays scheduled to be substantially complete by end of fiscal 2019. No employee count disclosed.
2017-07-28divestiture_reductioncompleted2017-07-29GlobalMinimally Invasive Therapies Group — Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businessesUSD 47 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture to Cardinal Health completed July 29, 2017 for $6.1 billion total consideration; $47M divestiture-related items recognized in Q1 FY2018 (legal/advisory and accelerated stock compensation). No headcount associated with the divested businesses disclosed.
2017-07-28restructuringin_progress2019-04-27GlobalAll reportable segmentsUSD 19 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost synergies initiative related to Covidien integration. Cash outlays scheduled to be substantially complete by end of fiscal year 2019. Charges primarily related to employee termination costs and manufacturing/facility closures.
2017-07-28restructuringin_progressCost of Sales [Member] / Cost Synergies Initiative [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-28restructuringin_progressSelling, General and Administrative Expenses [Member] / Cost Synergies Initiative [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-28restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-28restructuringin_progressOther Restructuring [Member] / Cost Synergies Initiative [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-28restructuringin_progressCost Synergies Initiative [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-28restructuringin_progress20152019-04All reportable segmentsUSD 368 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Covidien integration cost synergies program initiated in the fourth quarter of fiscal 2015, targeting approximately $850 million of synergies through fiscal 2018. Fiscal 2017 charges per the roll-forward table: $368 million (employee termination costs $287 million, asset write-downs $27 million, other costs $54 million), partially offset by $68 million of reversals of excess reserves; restructuring reserve of $291 million at April 28, 2017. MD&A reports total FY2017 restructuring charges of $441 million, which includes the $73 million voluntary early retirement component captured as a separate record. Headcount affected not disclosed. Cash outlays scheduled to be substantially complete by the end of fiscal 2019.
2017-04-28voluntary_separationcompletedUnited StatesUSD 73 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Voluntary early retirement packages offered to eligible U.S. employees during fiscal 2017 as part of the cost synergies initiative; acceptances drove $73 million of incremental defined benefit pension and post-retirement expense ($60 million U.S. pension, $7 million U.S. post-retirement, $4 million defined contribution plans, $2 million cash payments and administrative fees), accounted for under pension rules and excluded from the restructuring roll-forward table. Number of participating employees not disclosed.
2017-04-28divestiture_reductionannounced2017-04-18Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses (Patient Monitoring & Recovery division, Minimally Invasive Therapies Group)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		Definitive agreement announced April 18, 2017 to sell these businesses to Cardinal Health, Inc. for $6.1 billion in cash (after-tax proceeds estimated at approximately $5.5 billion), including 17 dedicated manufacturing facilities; the businesses generated net sales of $2.4 billion in fiscal 2017. Expected to close in the second quarter of fiscal 2018 subject to regulatory approvals; U.S. FTC clearance obtained in May 2017. Employee headcount affected not disclosed; Respiratory & Monitoring Solutions and Renal Care Solutions businesses retained.
2017-04-28acquisition_additioncompleted2016-08-232016-08-23Cardiac and Vascular Groupbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired HeartWare International, Inc. on August 23, 2016 for total consideration of approximately $1.1 billion; the acquired company develops and manufactures ventricular assist devices. Sales attributable to HeartWare were $155 million in fiscal 2017. Number of employees added through the acquisition not disclosed.
2017-04-28acquisition_additioncompleted2016-08-052016-08-05Minimally Invasive Therapies Group (Surgical Solutions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired Smith & Nephew's gynecology business on August 5, 2016 for total consideration of approximately $350 million. Sales attributable to the business were $45 million in fiscal 2017. Number of employees added through the acquisition not disclosed.
2017-04-28restructuringin_progress2015-01-262019-04-26GlobalAll reportable segmentsUSD 441 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Covidien integration cost synergies program; $441M of charges recognized in fiscal year 2017, including $73M of incremental pension/post-retirement expense for voluntary early retirement and $68M of reversals of excess reserves. Restructuring accrual balance $291M at April 28, 2017. Cash outlays scheduled to be substantially complete by end of fiscal year 2019. Employees affected not disclosed; program targets approximately $850M of cost synergies through fiscal year 2018.
2017-04-28voluntary_separationcompletedUnited StatesCorporate / U.S. employeesUSD 73 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Voluntary early retirement packages offered to eligible U.S. employees during fiscal year 2017; $73M of incremental expense ($60M U.S. pension, $7M post-retirement, $4M defined contribution, $2M cash/administrative). Number of participating employees not disclosed.
2017-04-28acquisition_additioncompleted2016-08-232016-08-23GlobalCardiac and Vascular Groupbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total consideration approximately $1.1 billion; acquired $427M of goodwill. Headcount added not disclosed; sales attributable to HeartWare were $155M in fiscal year 2017.
2017-04-28acquisition_additioncompleted2016-08-052016-08-05GlobalMinimally Invasive Therapies Groupbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total consideration approximately $350 million; acquired $180M of goodwill. Headcount added not disclosed; sales attributable were $45M in fiscal year 2017.
2017-04-28divestiture_reductionannounced2017-04-182017-07-28GlobalMinimally Invasive Therapies Group — Patient Monitoring & Recovery (Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement with Cardinal Health Inc. to sell three businesses for $6.1 billion cash (approximately $5.5 billion after tax); expected to close in second quarter of fiscal year 2018 subject to regulatory approvals. Transaction includes 17 dedicated manufacturing facilities. Net sales of divested businesses were $2.4 billion in fiscal years 2017 and 2016. Employees affected not disclosed; assets held for sale of $6.29 billion and liabilities held for sale of $754 million at April 28, 2017.
2017-04-28restructuringin_progress2019-04-30GlobalAll segmentsUSD 363 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Cost synergies initiative related to Covidien acquisition. Cash outlays expected substantially complete by end of fiscal 2019. Includes $73 million of incremental defined benefit pension and post-retirement expenses for voluntary early retirement packages.
2017-04-28acquisition_additioncompleted2016-08-23GlobalCardiac and Vascular GroupItem 1. Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of HeartWare International, Inc. completed August 23, 2016.
2017-04-28acquisition_additioncompleted2016-08-05GlobalMinimally Invasive Therapies GroupItem 1. Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Smith & Nephew's gynecology business completed August 5, 2016.
2017-04-28restructuringin_progress2015-01-262019-04-26GlobalAll segmentsUSD 363 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Cost synergies initiative related to the acquisition of Covidien. Cash outlays expected to be substantially complete by the end of fiscal year 2019. Includes $73 million of incremental defined benefit pension and post-retirement related expenses for voluntary early retirement packages.
2017-04-28voluntary_separationcompletedUnited StatesAll segmentsUSD 73 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Voluntary early retirement packages offered to eligible U.S. employees. Charge represents incremental defined benefit pension and post-retirement related expenses.
2017-04-28restructuringin_progressAsset Write-downs [Member] / Cost Synergies Initiative [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-04-28restructuringin_progressContract Termination and Other Costs [Member] / Cost Synergies Initiative [Member]USD 54,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-04-28restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 287,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-04-28restructuringin_progressCost Synergies Initiative [Member]USD 368,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-01-27restructuringin_progress2018-04-28USD 214 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Covidien integration cost synergies initiative; nine-month restructuring charges of $214 million partially offset by $42 million reversals; charges primarily employee termination costs and manufacturing/facility closure costs; restructuring accrual of $209 million at quarter-end, of which $179 million relates to employee termination costs; no employee counts disclosed
2017-01-27restructuringin_progressGlobalEnterprise (Covidien integration)USD 214 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program began in Q4 fiscal 2015 to deliver approximately $850 million of Covidien integration cost synergies through fiscal year 2018; charges expected quarterly through fiscal 2017 and beyond. Nine-month gross charges of $214 million were partially offset by $42 million of reserve reversals (net $162 million in the income statement). No employee headcount affected is disclosed; accrual balance was $209 million at period end. Announcement date not stated in filing.
2017-01-27othercompletedUnited StatesCorporate (Medtronic Foundation)USD 100 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Recorded as a $100 million special charge in the quarter: a charitable cash contribution to the Medtronic Foundation. Not a headcount action; included only because it is a discrete special charge disclosed this quarter with no workforce component. No employees affected.
2017-01-27restructuringin_progress2018-04-28USD 214 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost Synergies Initiative related to Covidien integration. Expected to contribute to $850 million in cost synergies through fiscal year 2018. Charges include employee termination costs and facility closures. No specific headcount affected disclosed for the period.
2017-01-27restructuringin_progressCost Synergies Initiative [Member]USD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-01-27restructuringin_progressAsset Write-downs [Member] / Cost Synergies Initiative [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-01-27restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 152,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-01-27restructuringin_progressOther Restructuring [Member] / Cost Synergies Initiative [Member]USD 44,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-28restructuringin_progress2018-04-28USD 47 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Covidien integration cost synergies initiative; $47M charge in Q2 and $158M YTD, primarily employee termination costs; no employee counts disclosed. Total restructuring liability of $227M at quarter-end; synergies of approximately $850M expected through fiscal year 2018
2016-10-28acquisition_additioncompleted2016-08-23Cardiac and Vascular GroupUSD 1,100 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of HeartWare, maker of ventricular assist devices; total consideration approximately $1.1 billion; no headcount figures disclosed
2016-10-28acquisition_additioncompleted2016-08-05Minimally Invasive Therapies GroupUSD 350 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Smith & Nephew's gynecology business for approximately $350 million; no headcount figures disclosed
2016-10-28restructuringin_progress20152018-04-28GlobalCompany-wide — Covidien integration (cost synergies initiative)USD 158 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program began in Q4 of fiscal 2015; targets approximately $850M of Covidien cost synergies through fiscal 2018. Restructuring charges of $158M recognized in the six months ended Oct 28, 2016, including $47M in the quarter; primarily employee termination costs. No headcount affected is disclosed. Restructuring accrual was $227M at quarter-end. Announcement date given only as year (program start).
2016-10-28acquisition_additioncompleted2016-08-23Cardiac and Vascular Groupbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of HeartWare International closed Aug 23, 2016 for approximately $1.1B consideration; acquired $602M of technology/customer intangibles, $23M tradenames, $479M goodwill. Headcount added through the acquisition is not disclosed.
2016-10-28acquisition_additioncompleted2016-08-05Minimally Invasive Therapies Groupbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Smith & Nephew's gynecology business closed Aug 5, 2016 for approximately $350M, primarily an upfront payment; $167M other intangibles and $180M goodwill recorded. Headcount added through the acquisition is not disclosed.
2016-10-28restructuringin_progress2018-04-28GlobalCorporate / All SegmentsUSD 47 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost Synergies Initiative related to Covidien integration. Charges consist primarily of employee termination costs. Total expected synergies $850M through FY2018.
2016-10-28restructuringin_progress2018-04-28GlobalCorporate / All SegmentsUSD 158 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD Cost Synergies Initiative charges. Includes $10M inventory write-offs and $7M reversal of excess accruals.
2016-10-28restructuringin_progressCost Synergies Initiative [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-28restructuringin_progressAsset Write-downs [Member] / Cost Synergies Initiative [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-28restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 117,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-28restructuringin_progressOther Restructuring [Member] / Cost Synergies Initiative [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-29restructuringin_progress2018-04-28USD 111 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Covidien integration cost synergies program; charges primarily employee termination costs ($77M) and asset write-downs ($14M); no employee count disclosed. Program targets ~$850M in cost synergies through fiscal year 2018; restructuring accrual of $256M at July 29, 2016.
2016-07-29restructuringin_progressGlobalCompany-wide (Covidien integration)USD 111 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program began in fiscal year 2015 Q4; no announcement date or headcount disclosed. Q1 FY2017 charges of $111M comprise $77M employee termination, $14M asset write-downs (incl. $10M inventory in COGS, $4M PP&E) and $20M other, offset by a $7M reversal of excess accrual. Severance/other accrual balance $256M at 2016-07-29. Targets ~$850M cost synergies through fiscal year 2018.
2016-07-29acquisition_additioncompleted2016-08-232016-08-23GlobalCardiac and Vascular Groupsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition for total consideration of approximately $1.1 billion; no headcount added disclosed.
2016-07-29acquisition_additioncompleted2016-08-052016-08-05GlobalMinimally Invasive Therapies Groupsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition for total consideration of approximately $350 million; no headcount added disclosed.
2016-07-29restructuringin_progress2018-04-28GlobalVarious (Administrative, Manufacturing, Supply Chain)USD 111 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost Synergies Initiative related to Covidien integration. $111M charge incurred in Q1 FY2017 ($77M employee termination, $14M asset write-downs, $20M other). Expected to contribute to $850M synergies through FY2018. Employee count not explicitly disclosed for this quarter's activity.
2016-07-29restructuringin_progressAsset Write-downs [Member] / Cost Synergies Initiative [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-29restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 77,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-29restructuringin_progressOther Restructuring [Member] / Cost Synergies Initiative [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-29restructuringin_progressCost Synergies Initiative [Member]USD 111,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-29restructuringin_progress2018USD 332 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Program began in the fourth quarter of fiscal 2015 in connection with the Covidien acquisition; approximately $850 million of cost synergies targeted through fiscal 2018. Fiscal 2016 charges of $332 million included $248 million of employee termination costs and were offset by an $18 million reversal of excess accruals; accrual balance of $250 million at April 29, 2016, with wind-down scheduled substantially complete within one year of each charge. No employee headcount figures disclosed for the program.
2016-04-29restructuringin_progress2018Pre-acquisition Covidien operationsrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Covidien's pre-acquisition program (corporate expense reduction, shared services expansion, manufacturing consolidation, distribution optimization). Fiscal 2016 activity was $61 million of payments/write-downs and a $10 million reversal of excess accruals, leaving a $7 million accrual at April 29, 2016; scheduled substantially complete by end of fiscal 2018. No new fiscal 2016 charges and no employee headcount figures disclosed.
2016-04-29acquisition_additionannounced2016-05-182017Minimally Invasive Therapies GroupUSD 350 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Post-year-end definitive agreement to acquire Smith & Nephew's gynecology business, expected to close in fiscal 2017. Value shown is transaction consideration, not a severance charge; workforce impact not disclosed.
2016-04-29acquisition_additionannounced2016-06-272017Cardiac Rhythm & Heart FailureUSD 1,100 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Post-year-end definitive agreement to acquire HeartWare International, expected to close in fiscal 2017; heart failure product portfolio complements the existing cardiac rhythm and heart failure business. Value shown is transaction consideration, not a severance charge; workforce impact not disclosed.
2016-04-29restructuringin_progressGlobalCompany-wide — administrative office optimization, manufacturing and supply chain infrastructure, and general and administrative savingsUSD 332 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program initiated in Q4 of fiscal year 2015 in connection with the Covidien acquisition; exact announcement date not disclosed. $332 million of gross restructuring charges incurred in fiscal year 2016, including $9 million of inventory write-offs recorded in cost of products sold, partially offset by reversals of excess accruals. Supports approximately $850 million of expected cost synergies through fiscal year 2018. Employees affected not disclosed; restructuring liabilities were $257 million at April 29, 2016.
2016-04-29restructuringin_progress2015-01-26GlobalCovidien legacy operations — corporate expense reduction, shared services, manufacturing consolidation, distribution center optimizationUSD 0 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pre-existing Covidien program assumed at the January 26, 2015 acquisition date with a $103 million reserve. No new restructuring charges in fiscal year 2016; $10 million reversal of excess accrual recorded, leaving a $7 million balance at April 29, 2016. Scheduled to be substantially complete by the end of fiscal year 2018. Employees affected not disclosed.
2016-04-29acquisition_additioncompleted2015-08-11Surgical Solutions division (Minimally Invasive Therapies Group)USD 240 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total consideration approximately $240 million for a retained-surgical-sponge detection company. Headcount added not disclosed.
2016-04-29acquisition_additioncompleted2015-08-31Neurovascular division (Restorative Therapies Group)USD 219 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total consideration approximately $219 million, including $64 million of contingent consideration; Medtronic previously held an 11 percent stake. Headcount added not disclosed.
2016-04-29acquisition_additioncompleted2015-10-02Coronary & Structural Heart division (Cardiac and Vascular Group)USD 472 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total consideration approximately $472 million for a transcatheter mitral valve replacement developer, including $44 million of contingent consideration. Headcount added not disclosed.
2016-04-29acquisition_additioncompletedVariousUSD 640 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Aggregate net assets acquired of $640 million from unnamed fiscal year 2016 acquisitions; individual transaction dates and headcount not disclosed.
2016-04-29acquisition_additionannounced2016-05-18Minimally Invasive Therapies Group (gynecology business)USD 350 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed after fiscal year-end to acquire Smith & Nephew's gynecology business for approximately $350 million; expected to close in fiscal year 2017. Headcount not disclosed.
2016-04-29acquisition_additionannounced2016-06-27Cardiac and Vascular Group (heart failure)USD 1,100 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement announced after fiscal year-end to acquire HeartWare International, Inc. for approximately $1.1 billion; expected to close in fiscal year 2017. Headcount not disclosed.
2016-04-29restructuringin_progress2015-04-242018-04-27GlobalVariousUSD 332 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Cost synergies initiative related to Covidien acquisition. Includes employee termination costs, asset write-downs, and other costs. No specific employee count disclosed for FY2016 activity.
2016-04-29restructuringin_progress2015-04-302018-04-28GlobalAll segmentsUSD 332 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cost synergies initiative related to Covidien acquisition. Fiscal 2016 charges of $332M include employee termination costs, asset write-downs, and other costs. Program expected to be substantially complete by FY2018.
2016-04-29restructuringin_progress2015-01-262018-04-28GlobalAll segmentsUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Covidien pre-acquisition restructuring program. No new charges in FY2016; reversals of excess accruals of $10M recorded. Program expected to be substantially complete by FY2018.
2016-04-29restructuringin_progressAsset Write-downs [Member] / Cost Synergies Initiative [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-04-29restructuringin_progressContract Termination and Other Costs [Member] / Cost Synergies Initiative [Member]USD 61,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-04-29restructuringin_progressContract Termination and Other Costs [Member] / Covidien Initiative [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-04-29restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 248,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-04-29restructuringin_progressEmployee Severance [Member] / Covidien Initiative [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-04-29restructuringin_progressCost Synergies Initiative [Member]USD 332,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-04-29restructuringin_progressCovidien Initiative [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-01-29restructuringin_progress2015-01-262018-04-28Administrative office optimization, manufacturing and supply chain infrastructure, general and administrative savingsUSD 55 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cost synergies initiative tied to Covidien acquisition; $55M net charge in Q3 after $19M reversal of excess accruals; charges expected through fiscal 2017 and beyond; ~$850M total synergies targeted through fiscal 2018
2016-01-29restructuringin_progress2015-01-262018-04-28Legacy Covidien cost structure (corporate expenses, shared services, manufacturing, distribution)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pre-acquisition Covidien program; $103M reserved at acquisition date; $2M reversal of excess accrual in Q3 FY2016; scheduled to be substantially complete by end of fiscal 2018
2016-01-29restructuringin_progress2015-04-252018-04-29GlobalMultiple — cost synergies initiative related to Covidien acquisitionUSD 208 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month restructuring charges of $208M (gross) partially offset by $32M reversal of excess reserves; no employee headcount disclosed. Program targets ~$850M cost synergies through FY2018.
2016-01-29restructuringin_progress2015-04-252018-04-29GlobalLegacy Covidien operationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-acquisition Covidien restructuring program; $14M payments during Q3 FY2016 with $2M reversal of excess reserves; no employee headcount disclosed.
2016-01-29restructuringin_progress2015-10-012018-04-29GlobalCorporate and AdministrativeUSD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost synergies initiative related to Covidien acquisition. Q3 charges of $55M include $36M employee termination costs, $12M asset write-downs, and $7M other costs. Includes $19M reversal of excess accrual.
2016-01-29restructuringin_progress2015-01-262018-04-29GlobalCorporate and AdministrativeUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Covidien pre-acquisition restructuring program. Q3 payments of $14M and $2M reversal of excess accrual. No new charges recorded in Q3.
2016-01-29restructuringin_progressAsset Write-downs [Member] / Cost Synergies Initiative [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-01-29restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-01-29restructuringin_progressOther Restructuring [Member] / Cost Synergies Initiative [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-01-29restructuringin_progressCost Synergies Initiative [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-10-30restructuringin_progress2015-01-26Company-wide cost synergies initiative related to Covidien acquisitionUSD 86 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 FY2016 charge of $86M: employee termination costs $64M, asset write-downs $10M, other costs $12M; partially offset by $13M reversal of excess restructuring reserves. Program targets ~$850M in cost synergies through fiscal year 2018; charges expected quarterly through FY2016 and beyond. No employee headcount affected disclosed.
2015-10-30restructuringin_progress2015-01-262018-04-29Legacy Covidien cost structure programrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pre-acquisition Covidien restructuring program (corporate expense reduction, shared services expansion, manufacturing consolidation, distribution optimization); scheduled to be substantially complete by end of fiscal year 2018. Reserve of $103M recorded at Acquisition Date; balance of $46M at October 30, 2015. No employee headcount affected disclosed.
2015-10-30restructuringin_progress2014-10-012018-04-30GlobalEnterprise-wide (cost synergies from Covidien acquisition)USD 86 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 FY2016 charge of $86M (employee termination $64M, asset write-downs $10M, other $12M), offset by $13M reversal of excess reserves. YTD FY2016 charges $153M gross, $140M net. No employee headcount disclosed. Part of ~$850M cost synergy target through FY2018.
2015-10-30restructuringin_progress2015-01-262018-04-30GlobalLegacy Covidien operationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-acquisition Covidien restructuring program; $103M reserved at acquisition date. No charges recorded in current quarter. No employee headcount disclosed. Scheduled to be substantially complete by end of FY2018.
2015-10-30acquisition_additioncompleted2015-10-022015-10-02United StatesCoronary & Structural Heart divisionUSD 472 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Twelve, Inc., a transcatheter mitral valve replacement developer. Total consideration ~$472M. No employee headcount disclosed.
2015-10-30acquisition_additioncompleted2015-08-112015-08-11United StatesSurgical Solutions divisionUSD 240 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of RF Surgical Systems, Inc., a retained surgical sponge detection company. Total consideration ~$240M. No employee headcount disclosed.
2015-10-30acquisition_additioncompleted2015-08-312015-08-31United StatesNeurovascular divisionUSD 219 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Medina Medical, a cerebral aneurysm treatment developer. Total consideration ~$219M including contingent consideration. No employee headcount disclosed.
2015-10-30restructuringin_progress2015-01-262018-04-28GlobalCorporate / All SegmentsUSD 86 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost synergies initiative related to Covidien acquisition. Q2 charge of $86M includes $64M employee termination costs. Program expected to be substantially complete by end of fiscal 2018.
2015-10-30restructuringin_progress2015-01-262018-04-28GlobalCorporate / All SegmentsUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Covidien pre-acquisition restructuring initiative. Q2 payments of $14M. Program scheduled to be substantially complete by end of fiscal 2018.
2015-10-30restructuringin_progressAsset Write-downs [Member] / Cost Synergies Initiative [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-10-30restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 64,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-10-30restructuringin_progressOther Restructuring [Member] / Cost Synergies Initiative [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-10-30restructuringin_progressCost Synergies Initiative [Member]USD 86,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-07-31restructuringin_progressUSD 67 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 FY2016 charge under cost synergies initiative tied to Covidien acquisition; primarily employee termination costs of $52 million plus $15 million other costs. Restructuring accruals expected to be substantially complete within one year of the quarter incurred; charges expected quarterly through FY2016 and beyond.
2015-07-31restructuringin_progress2018-04-28restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Legacy Covidien pre-acquisition program to reduce corporate expenses, expand shared services, consolidate manufacturing, and optimize distribution centers; scheduled to be substantially complete by end of fiscal year 2018. Reserve of $60 million remained at July 31, 2015; $18 million paid during the quarter.
2015-07-31restructuringin_progress2016-04-30GlobalEnterprise-wide (Covidien integration cost synergies)USD 67 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 FY2016 charge comprised $52M employee termination costs and $15M other costs; no headcount disclosed. Program supports ~$850M of Covidien cost synergies targeted through FY2018; accruals expected substantially complete within one year of initial charge (Q4 FY2015). Total restructuring liabilities $195M at 2015-07-31.
2015-07-31restructuringin_progress2015-01-262018-04-30GlobalLegacy Covidien operationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-acquisition Covidien cost-reduction program; $103M reserve recorded at Acquisition Date (2015-01-26), $60M accrual balance remaining at 2015-07-31 after $18M payments in the quarter. No employee counts or current-period charge disclosed.
2015-07-31restructuringin_progress2018-04-30USD 67 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost Synergies Initiative related to Covidien acquisition. Charges consist primarily of employee termination costs ($52M) and other related costs ($15M). Program expected to be substantially complete by end of fiscal year 2018.
2015-07-31restructuringin_progress2018-04-30restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Covidien Initiative (pre-acquisition restructuring). No new charges recorded in Q1 FY2016; payments of $18M made against existing reserves. Program scheduled to be substantially complete by end of fiscal year 2018.
2015-07-31restructuringin_progressContract Termination and Other Costs [Member] / Cost Synergies Initiative [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-07-31restructuringin_progressEmployee Severance [Member] / Cost Synergies Initiative [Member]USD 52,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-07-31restructuringin_progressCost Synergies Initiative [Member]USD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-04-24restructuringin_progress2015-042016-04Covidien integration; manufacturing process alignment; inventory rationalization; program cancellationsUSD 248 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Charge recorded in Q4 fiscal 2015; comprises $213 million employee termination costs, $28 million asset write-downs, $6 million contract termination and $1 million other. Primarily relates to the Covidien acquisition; management anticipates roughly $850 million of Covidien cost synergies through fiscal 2018. Further charges expected quarterly through fiscal 2016, primarily employee termination and site-closure costs. Scheduled to be substantially complete by end of Q4 fiscal 2016. Employees affected not disclosed.
2015-04-24acquisition_additioncompleted2015-01-262015-01-26business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Covidien plc completed January 26, 2015 for total consideration of approximately $50 billion. Number of employees added is not disclosed; Item 6 shows year-end full-time equivalent employees of 92,500 in fiscal 2015 versus 49,247 in fiscal 2014. Covidien's pre-acquisition restructuring program was assumed with the transaction.
2015-04-24restructuringin_progress2018-04Corporate expense reduction; shared services expansion; manufacturing consolidation; distribution center optimizationrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Covidien's pre-acquisition cost-structure program assumed with the January 26, 2015 acquisition. Fiscal 2015 activity: $5 million reversal of excess reserves in Q4; remaining liabilities of $78 million at April 24, 2015, including $61 million for employee termination costs. Scheduled to be substantially complete by end of fiscal 2018. Employees affected not disclosed.
2015-04-24restructuringcompleted2014-042015-04-24Europe (back-office support reduction)Renal denervation business; manufacturing shutdowns; back-office support functionsUSD 38 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Program initiated with a $116 million charge in Q4 fiscal 2014. Final charge of $38 million recorded in Q1 fiscal 2015 (value shown), plus a $17 million reversal of excess reserves during fiscal 2015. Substantially complete as of April 24, 2015 with $9 million liabilities remaining. Employees affected not disclosed.
2015-04-24restructuringcompleted2013-042015-04-24Infrastructure scale-back in slower-growing areasrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Program initiated with a $192 million charge in Q4 fiscal 2013 and an $18 million final charge in Q1 fiscal 2014. Fiscal 2015 activity limited to a $10 million reversal of excess reserves. Substantially complete as of April 24, 2015. Employees affected not disclosed.
2015-04-24restructuringin_progress2016-04-29GlobalMultiple; related to Covidien acquisition, manufacturing process alignment, inventory rationalization, program cancellationsUSD 248 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charge recorded in Q4 FY2015: $213M employee termination costs, $28M asset write-downs (of which $15M in cost of products sold), $6M contract termination, $1M other; scheduled substantially complete by end of Q4 fiscal 2016; headcount affected not disclosed; part of program targeting approximately $850M cost synergies through fiscal 2018
2015-04-24restructuringin_progress2015-01-262018-04-27GlobalCovidien legacy operations (corporate, manufacturing, distribution)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pre-acquisition Covidien program assumed at acquisition date with $103M accrual ($76M employee termination, $27M other); FY2015 activity was a $5M reversal of excess accrual and $20M payments; scheduled substantially complete by end of fiscal 2018; employees affected not disclosed
2015-04-24restructuringcompleted2015-04-24Global; includes Europe back-office support functionsRenal denervation business, manufacturing shut-downs, European back-office supportUSD 38 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Current-fiscal-year activity only: $38M final charge recorded in Q1 FY2015 (contract termination and other costs), plus $17M reversal of excess reserves; program substantially complete as of April 24, 2015; original $116M charge recorded in FY2014 is prior-year activity and excluded
2015-04-24restructuringcompleted2015-04-24GlobalInfrastructure in slower-growing areas of the businessrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Current-fiscal-year activity only: $10M reversal of excess restructuring reserves recorded in FY2015; no new charges; program substantially complete as of April 24, 2015; original $192M charge recorded in FY2013 is prior-year activity and excluded
2015-04-24acquisition_additioncompleted2014-06-152015-01-26GlobalMinimally Invasive Therapies Group, Cardiac and Vascular Group, Restorative Therapies Groupbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately $50 billion cash-and-stock acquisition closed January 26, 2015; headcount added not quantified in the filing; full-time equivalent employees rose from 49,247 at FY2014 year-end to 92,500 at FY2015 year-end
2015-04-24restructuringin_progress2015-01-262018-04-30GlobalAll SegmentsUSD 248 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Fiscal year 2015 initiative related to Covidien acquisition. Includes employee termination costs of $213 million, asset write-downs of $28 million, and other costs. Expected to be substantially complete by end of Q4 FY2016. Part of broader $850 million cost synergy target through FY2018.
2015-04-24restructuringcompleted2014-01-012015-04-24GlobalAll SegmentsUSD 38 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Fiscal year 2014 initiative. Final charge of $38 million recorded in Q1 FY2015. Substantially complete as of April 24, 2015.
2015-04-24restructuringcompleted2013-01-012015-04-24GlobalAll Segmentsrestructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Fiscal year 2013 initiative. Substantially complete as of April 24, 2015. No new charges recorded in FY2015; only reversals of excess reserves.
2015-04-24restructuringin_progress2015-01-262018-04-28GlobalAll segmentsUSD 248 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Fiscal Year 2015 Initiative related to Covidien acquisition. Charge includes $213M employee termination costs, $28M asset write-downs, $6M contract termination, $1M other. Expected to be substantially complete by end of Q4 FY2016. Part of program targeting $850M synergies through FY2018.
2015-04-24restructuringin_progress2014-04-272015-04-24GlobalAll segmentsUSD 38 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Fiscal Year 2014 Initiative. Final charge of $38M recorded in Q1 FY2015. Initiative substantially complete as of April 24, 2015.
2015-04-24restructuringcompleted2013-04-282015-04-24GlobalAll segmentsrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Fiscal Year 2013 Initiative. Substantially complete as of April 24, 2015. No new charges recorded in FY2015, only reversals of excess reserves.
2015-04-24restructuringin_progressContract Termination and Other Costs [Member] / Covidien Initiative [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressEmployee Severance [Member] / Covidien Initiative [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressCovidien Initiative [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressAsset Write-downs [Member] / Fiscal Year 2015 Initiative [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressInventory Write-Offs [Member] / Fiscal Year 2015 Initiative [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressContract Termination [Member] / Fiscal Year 2015 Initiative [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressEmployee Severance [Member] / Fiscal Year 2015 Initiative [Member]USD 213,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressOther Restructuring [Member] / Fiscal Year 2015 Initiative [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressFiscal Year 2015 Initiative [Member]USD 248,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressAsset Write-downs [Member] / Fiscal Year 2014 Initiative [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressContract Termination and Other Costs [Member] / Fiscal Year 2014 Initiative [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressContract Termination and Other Costs [Member] / Fiscal Year 2015 Initiative [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressEmployee Severance [Member] / Fiscal Year 2014 Initiative [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-04-24restructuringin_progressFiscal Year 2014 Initiative [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-01-23acquisition_additioncompleted2014-06-152015-01-26GlobalAllsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Covidien acquisition and Medtronic merger closed 2015-01-26, three days after quarter end; both became subsidiaries of Medtronic plc. No employee counts disclosed; preliminary purchase accounting incomplete at filing date.